

Queensland Clinical Guidelines

Translating evidence into best clinical practice

Maternity and Neonatal **Clinical Guideline**

Stabilisation for retrieval–neonatal

Document title:	Stabilisation for retrieval–neonatal
Publication date:	November 2023
Document number:	MN23.18-V5-R28
Document supplement:	The document supplement details development processes and implementation activities, and is integral to and should be read in conjunction with this guideline
Amendments:	Full version history is supplied in the document supplement
Amendment date:	November 2023
Replaces document:	MN18.18-V4-R23
Author:	Queensland Clinical Guidelines
Audience:	Health professionals in Queensland public and private maternity and neonatal services
Review date:	November 2028
Endorsed by:	Queensland Clinical Guidelines Steering Committee Statewide Maternity and Neonatal Clinical Network (Queensland)
Contact:	Email: Guidelines@health.qld.gov.au URL: www.health.qld.gov.au/qcg



Acknowledgement

The Department of Health acknowledges the Traditional Custodians of the land, waters and seas across the State of Queensland on which we work and live. We also acknowledge First Nations peoples in Queensland are both Aboriginal Peoples and Torres Strait Islander Peoples and pay our respect to the Aboriginal and Torres Strait Islander Elders past, present and emerging.

Disclaimer

This guideline is intended as a guide and provided for information purposes only. The information has been prepared using a multidisciplinary approach with reference to the best information and evidence available at the time of preparation. No assurance is given that the information is entirely complete, current, or accurate in every respect.

The guideline is not a substitute for clinical judgement, knowledge and expertise, or medical advice. Variation from the guideline, taking into account individual circumstances, may be appropriate.

This guideline does not address all elements of standard practice and accepts that individual clinicians are responsible for:

- Providing care within the context of locally available resources, expertise, and scope of practice
- Supporting consumer rights and informed decision making, including the right to decline intervention or ongoing management
- Advising consumers of their choices in an environment that is culturally appropriate and which enables comfortable and confidential discussion. This includes the use of interpreter services where necessary
- Ensuring informed consent is obtained prior to delivering care
- Meeting all legislative requirements and professional standards
- Applying standard precautions, and additional precautions as necessary, when delivering care
- Documenting all care in accordance with mandatory and local requirements

Queensland Health disclaims, to the maximum extent permitted by law, all responsibility and all liability (including without limitation, liability in negligence) for all expenses, losses, damages and costs incurred for any reason associated with the use of this guideline, including the materials within or referred to throughout this document being in any way inaccurate, out of context, incomplete or unavailable.

Recommended citation: Queensland Clinical Guidelines. Stabilisation for retrieval–neonatal Guideline No. MN23.18-V5-R28. Queensland Health. 2023 Available from: <http://www.health.qld.gov.au/qcg>


© State of Queensland (Queensland Health) 2023



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives V4.0 International licence. In essence, you are free to copy and communicate the work in its current form for non-commercial purposes, as long as you attribute Queensland Clinical Guidelines, Queensland Health and abide by the licence terms. You may not alter or adapt the work in any way. To view a copy of this licence, visit <https://creativecommons.org/licenses/by-nc-nd/4.0/deed.en>

For further information, contact Queensland Clinical Guidelines, RBWH Post Office, Herston Qld 4029, email Guidelines@health.qld.gov.au. For permissions beyond the scope of this licence, contact: Intellectual Property Officer, Queensland Health, GPO Box 48, Brisbane Qld 4001, email ip_officer@health.qld.gov.au


Flowchart: Antenatal transfer or retrieval



CSCF: Clinical Services Capability Framework; **FGR:** Fetal growth restriction; **PROM:** Prelabour rupture of membranes; **PPROM:** Preterm prelabour rupture of membranes; **QCG:** Queensland Clinical Guidelines; **RSQ:** Retrieval Services Queensland


Flowchart: F23.18-1-V4-R28

Flowchart: Postnatal stabilisation and retrieval



BP: blood pressure; **CPAP:** continuous positive airway pressure; **CSCF:** Clinical Services Capability Framework; **EOGBSD:** early onset Group B Streptococcal disease; **ETT:** endotracheal tube; **FBC:** full blood count; **HIE:** hypoxic ischaemic encephalopathy; **HR:** heart rate; **IPPV:** intermittent positive pressure ventilation; **IV:** intravenous; **NGT:** nasogastric tube; **OGT:** orogastric tube; **QCG:** Queensland Clinical Guidelines; **RSQ:** Retrieval Services Queensland; **SGAD:** supraglottic airway device; **UVC:** umbilical vein catheter

Flowchart: Respiratory distress



BPM: breaths per minute; **cm H₂O:** centimetres of water; **CPAP:** continuous positive airway pressure; **ETT:** endotracheal tube; **IPPV:** intermittent positive pressure ventilation; **MAP:** mean airway pressure; **IT:** inspiratory time; **PaCO₂:** partial pressure of carbon dioxide; **PEEP:** positive end expiratory pressure; **PIP:** peak inspiratory pressure; **QCG:** Queensland Clinical Guidelines; **RDS:** respiratory distress syndrome; **RSQ:** Retrieval Services Queensland; **<:** less than; **>:** more than

Flowchart: 23.18-4-V5-R28

Table of Contents

Abbreviations	8
Definitions	8
1 Introduction	9
1.1 Clinical standards	9
1.2 Indications for transfer or retrieval	10
1.2.1 Antenatal considerations	10
1.2.2 Postnatal considerations	10
1.3 Referral for retrieval	11
1.4 Initial management	12
1.5 Resuscitation	12
1.6 Thermoregulation	13
1.7 Investigations	13
1.8 Clinical support	14
2 Observations and monitoring	15
2.1 Vital signs	15
3 Fluids and medication	16
4 Respiratory support	16
4.1 Continuous positive airway pressure	17
4.2 Surfactant	18
4.3 Intermittent positive pressure ventilation	18
4.3.1 Intubation	19
5 Glucose monitoring	19
6 Infection	20
6.1 Risk factors and signs of infection	20
6.2 Management of sepsis	21
7 Circulation	21
7.1 Fluid management	21
7.2 Hypovolaemic shock	22
8 Encephalopathy	23
8.1 Seizures	23
9 Pain management	24
10 Preparation for retrieval	25
10.1 Retrieval team	26
11 Parents	26
12 Specific conditions	27
12.1 Respiratory disorders	27
12.1.1 Air leaks—presentation and management	27
12.1.2 Choanal atresia	28
12.1.3 Pierre Robin sequence	28
12.2 Gastrointestinal disorders	29
12.2.1 Bowel anomalies	29
12.2.2 Abdominal wall anomalies	30
12.2.3 Abdominal wall anomalies continuing care	31
12.2.4 Oesophageal anomalies	32
12.2.5 Diaphragmatic hernia	33
12.3 Cardiac disorders	34
12.3.1 Duct dependent cardiac lesions	34
12.3.2 Non-duct dependent cardiac lesions	35
12.3.3 Cardiac arrhythmias	35
12.4 Neural tube anomalies	36
12.5 Other	37
12.5.1 Bone fractures	37
12.5.2 Skin conditions	38
References	39
Appendix A Checklist: Preparation for retrieval	43
Acknowledgements	45

List of Tables

Table 1. Clinical standards	9
Table 2. Antenatal.....	10
Table 3. Neonatal	10
Table 4. Information for Retrieval Services Queensland.....	11
Table 5. Resuscitation preparation.....	12
Table 6. Thermoregulation.....	13
Table 7. Investigations.....	13
Table 8. Clinical support	14
Table 9. Vital signs	15
Table 10. Fluid and medication	16
Table 11. Respiratory support	16
Table 12. Continuous positive airway pressure.....	17
Table 13. Surfactant	18
Table 14. Indications for IPPV	18
Table 15. Intubation	19
Table 16. Glucose monitoring and management	19
Table 17. Risk factors and signs of sepsis	20
Table 18. Management of sepsis	21
Table 19. Intravascular access.....	21
Table 20. Cardiovascular compromise	22
Table 21. Encephalopathy	23
Table 22. Seizures.....	23
Table 23. Pain.....	24
Table 24. Preparation for retrieval	25
Table 25. Retrieval team.....	26
Table 26. Parent considerations.....	26
Table 27. Air leaks	27
Table 28. Choanal atresia.....	28
Table 29. Pierre Robin sequence	28
Table 30. Bowel anomalies	29
Table 31. Abdominal wall anomalies	30
Table 32. Continuing care.....	31
Table 33. Oesophageal atresia and trachea-oesophageal fistula.....	32
Table 34. Diaphragmatic hernia	33
Table 35. Duct dependent cardiac lesions	34
Table 36. Non-duct dependent cardiac lesions	35
Table 37. Cardiac arrhythmias	35
Table 38. Neural tube anomalies.....	36
Table 39. Bone fractures	37
Table 40. Skin conditions.....	38

Abbreviations

BGL	Blood glucose level
CPAP	Continuous positive airway pressure
ECG	Electrocardiogram
EOGBSD	Early onset Group B Streptococcal disease
ETT	Endotracheal tube
FBC	Full blood count
HIE	Hypoxic ischaemic encephalopathy
ICC	Intercostal catheter
IM	Intramuscular
IPPV	Intermittent positive pressure ventilation
IV	Intravascular
LBW	Low birth weight
NBM	Nil by mouth
NGT	Nasogastric tube
NEC	Necrotising enterocolitis
OGT	Orogastric tube
OI	Osteogenesis imperfecta
PACS	Picture archiving communication system
PIP	Peak inspiratory pressure
PIVC	Peripheral intravenous access
RSI	Rapid sequence induction
QCG	Queensland Clinical Guidelines
RSQ	Retrieval Services Queensland
SGAD	Supraglottic airway device
SpO ₂	Capillary peripheral oxygen saturation
TGA	Transposition of the great arteries
UVC	Umbilical vein catheter
VSD	Ventricular septal defect

Definitions

CHARGE association	C oloboma of the eye, h eart anomalies, a tresia of the choanae, r estricted growth, g enital anomalies and e ar anomalies.
Cold stress	Body temperature between 36 °C and 36.5 °C.
Early onset sepsis	Onset of symptoms before 72 hours of age (although may present up to 6 days after birth).
Hypothermia	Body temperature less than 36 °C.
Reprogle tube	Double lumen tube inserted through the baby's mouth or nares into the blind ending oesophageal pouch and used to drain secretions.
VATER/VACTERL association	V ertebral anomalies, a nal atresia, c ardiac anomalies, t racheo-oesophageal fistula, r enal anomalies, l imb anomalies.
Woman/women	In QCG documents, the terms <i>woman</i> and <i>women</i> include people who do not identify as women but who are pregnant or have given birth.

1 Introduction

Antenatal transfer of the woman with a high-risk pregnancy reduces neonatal morbidity and mortality, and is the safest way to transport a high-risk fetus to a perinatal centre. Babies who unexpectedly require resuscitation outside a level 6 perinatal centre may require stabilisation and subsequent transfer or retrieval. If possible and in discussion with the parents, plan for the birth of a high-risk baby to occur in a facility with the anticipated level of neonatal service.¹ Despite best efforts, there will be times when in-utero transfer is not appropriate and a neonatal retrieval is required.²

If maternity services are provided within the facility's Clinical Service Capabilities Framework (CSCF) optimal outcomes for both the woman and her baby are more likely. Babies who are born outside of the local CSCF level may, be managed safely at the local level based on clinical decisions made in consultation with clinicians at higher CSCF levels.¹

Regardless of CSCF level, clinicians require skills in neonatal resuscitation, stabilisation and examination.¹ Initial resuscitation and stabilisation prior to transfer or retrieval of babies is critical to their long term outcomes². The risk of mortality and major morbidity increases with decreasing gestational age and is higher among out born babies compared with those born in a level 6 perinatal centre.^{2,3}

1.1 Clinical standards

Table 1. Clinical standards

Aspect	Consideration
Standard care	<ul style="list-style-type: none"> Refer to Queensland Clinical Guideline: Standard care⁴ for care considered 'usual' or 'standard' <ul style="list-style-type: none"> Includes for example: hand hygiene, privacy, consent, decision making, sensitive communication, medication administration, staff education and support, culturally appropriate care
Clinical guidelines	<ul style="list-style-type: none"> Refer to Queensland Clinical Guidelines: <ul style="list-style-type: none"> Early onset Group B Streptococcal disease⁵ Newborn hypoglycaemia⁶ Hypoxic-ischaemic encephalopathy⁷ Neonatal jaundice⁸ Neonatal medicines⁹ Newborn baby assessment (routine)¹⁰ Perinatal care of the extremely preterm baby¹¹ Perinatal substance use: neonatal¹² Respiratory distress and CPAP¹³ Neonatal resuscitation¹⁴ Neonatal seizures¹⁵
Consumer information	<ul style="list-style-type: none"> Refer to Queensland Clinical Guidelines consumer information including: <ul style="list-style-type: none"> Babies born very early¹⁶ Baby needing transfer¹⁷ Group B Streptococcus (GBS) in pregnancy¹⁸ Hypoxic ischaemic encephalopathy¹⁹ Jaundice in newborn babies²⁰ Hypoglycaemia in newborn baby²¹ Neonatal abstinence syndrome (NAS)²² Newborn resuscitation²³ Seizures in newborn babies²⁴ Small baby born at term²⁵
CSCF	<ul style="list-style-type: none"> Escalation for retrieval of baby is dependent on CSCF of birthing facility
Preparation	<ul style="list-style-type: none"> Anticipate care from antenatal diagnosis or condition Evaluate and organise resources—staff and equipment Contact Retrieval Services Queensland (RSQ) 1300 799 127 as soon as possible²⁶ RSQ will facilitate: <ul style="list-style-type: none"> Discussion with neonatologist and other specialist (as indicated) for advice and to support the management of the baby Retrieval activation (if required)

1.2 Indications for transfer or retrieval

Transfer or retrieval may be indicated when the required clinical care of the baby exceeds the CSCF of the birthing facility.¹ Where possible, transfer in-utero to a higher-level facility. If antenatal transfer of the woman is not possible, contact RSQ prior to birth for advice from a neonatologist. Early activation of the neonatal retrieval team can be made when indicated.

1.2.1 Antenatal considerations

Table 2. Antenatal

Aspect	Comment
Fetal ^{27,28}	<ul style="list-style-type: none"> • Known congenital anomaly including suspected cardiac anomaly • Multiple pregnancy • Fetal growth restriction
Maternal ^{27,28}	<ul style="list-style-type: none"> • Preterm labour • Antepartum haemorrhage; placenta praevia • Severe hypertensive disorder • Prolonged rupture of membranes

1.2.2 Postnatal considerations

Table 3. Neonatal

Aspect	Comment
Adaptation to extrauterine life	<ul style="list-style-type: none"> • An Apgar score of 6 or less at 5 minutes of age • Birth weight—low, very low or extremely low • Prematurity • Persistent hypothermia • Persistent hypoglycaemia [refer to Queensland Clinical Guideline: Newborn hypoglycaemia⁶]
Respiratory	<ul style="list-style-type: none"> • Conditions from any cause where the care exceeds CSCF capabilities [refer to Queensland Clinical Guideline: Respiratory distress and CPAP¹³] • Respiratory distress syndrome • Transient tachypnoea of the newborn (TTN) • Pneumonia • Persistent pulmonary hypertension of the newborn (PPHN) • Meconium aspiration syndrome • Air leaks (e.g. pneumothorax) • Recurrent apnoea • Mechanical ventilation
Other	<ul style="list-style-type: none"> • Infection or suspected sepsis • Bleeding from any site • Hyperbilirubinemia [refer to Queensland Clinical Guideline: Neonatal jaundice⁹] • Severe neonatal abstinence syndrome [refer to Queensland Clinical Guideline: Perinatal substance use: neonatal¹²]
Congenital anomaly	<ul style="list-style-type: none"> • Major congenital anomaly requiring specialist care and/or surgery (e.g. gastroschisis) • Suspected or confirmed congenital heart disease (excluding isolated ventricular septal defect (VSD))
Central nervous system disorder	<ul style="list-style-type: none"> • Seizures [refer to Queensland Clinical Guideline: Neonatal seizures¹⁵] • Neonatal encephalopathy including hypoxic-ischaemic encephalopathy (HIE) [refer to Queensland Clinical Guideline: Hypoxic-ischaemic encephalopathy¹⁹] • Central hypoventilation syndrome
Specialist care	<ul style="list-style-type: none"> • Need for special diagnostic and/or therapeutic services • Conditions requiring specialty management (e.g. surgery) • Refer to Section 12 Specific conditions

1.3 Referral for retrieval

RSQ provides a single point of contact and assists the most senior clinician available at the referring hospital to consult with the neonatologist. The neonatologist and RSQ will facilitate consultation for advice and further management with the retrieval team, and if indicated the appropriate subspecialists. These include for example, endocrinologist, neurologist, surgeon or cardiologist. Telemedicine/teleconferencing supports the referring clinicians with decision making, diagnosis and advice, and can be used as indicated and available.²⁶

A variety of transport modes including ambulance, fixed wing aircraft or helicopter are used for retrieval. The mode of transport used depends on:

- Clinical condition of the baby
- Urgency
- Transport availability
- Distance
- Weather conditions

Table 4. Information for Retrieval Services Queensland

Aspect	Consideration
General ²⁶	<ul style="list-style-type: none"> • Contact details of referring medical officer • Referring hospital • Parents' preference to travel with the baby if able [refer to Table 26. Parent considerations]
Maternal ²⁶	<ul style="list-style-type: none"> • Demographic information (name, date of birth, address, phone number) • Maternal history—antenatal and any pre-existing medical conditions • Perinatal history • Weight of parent (mother or father/partner) if accompanying baby on flight • Father/partner's full name if accompanying baby • Other (e.g. cultural, social, family or religious considerations)
Neonatal ²⁶	<ul style="list-style-type: none"> • Demographic information: <ul style="list-style-type: none"> ○ Name ○ Date of birth ○ Gestation ○ Weight ○ Sex • Birth details: <ul style="list-style-type: none"> ○ Time of birth ○ Mode of birth • Apgar scores and resuscitation required • Current observations—heart rate, respiration rate, blood pressure, capillary peripheral oxygen saturation (SpO₂), temperature, colour, respiratory effort, tone and other (e.g. seizure activity, apnoea, hyperbilirubinemia) • Investigations—pathology, imaging • Current management (e.g. airway management, oxygen requirement, fluids, medications) • Any known provisional or antenatal diagnosis of congenital anomaly • If suspected HIE, time cooling commenced • Any information that may affect the transfer (e.g. general concerns, suspected infection, infectious disease status)

1.4 Initial management

Some babies require ongoing support after initial resuscitation. The level of support will depend on the clinical condition of the individual baby. Consider the need for therapeutic hypothermia to commence within six hours of birth. Refer to Queensland Clinical Guideline: [Hypoxic-ischaemic encephalopathy](#).⁷

General principles of management include²⁹:

- Identify immediate needs
- Stabilise the baby and prevent deterioration
- Identify and initiate diagnostic investigations
- Establish and maintain communication with the baby's parent(s)
- Contact RSQ for advice, support and to activate retrieval as required

1.5 Resuscitation

Anticipate and plan for the baby's resuscitation prior to the birth. At birth, assess the need for immediate and ongoing resuscitation. Consider that the need for resuscitation can be due to onset of sepsis.

Refer to Queensland Clinical Guideline: [Neonatal resuscitation](#)¹⁴

Table 5. Resuscitation preparation

Aspect	Consideration
Staff	<ul style="list-style-type: none"> • Appropriate level of skill • Familiar with: <ul style="list-style-type: none"> ○ Equipment ○ Medications ○ Resuscitation trolley layout
Equipment	<ul style="list-style-type: none"> • Readily available for all births regardless of risk • Complete and operational • Refer to Queensland Clinical Guidelines: Neonatal resuscitation equipment checklist³⁰
Environment	<ul style="list-style-type: none"> • Preheated overhead radiant warmer positioned in a draft free area • Prewarmed blankets and hat • Babies less than 32+0 weeks gestation or low birth weight (LBW) may require a combination of additional measures³¹: <ul style="list-style-type: none"> ○ Increase birthing room temperature (if possible) ○ A polyethylene bag or sheet up to the baby's neck <ul style="list-style-type: none"> ▪ Particularly babies less than 28+0 weeks gestation ▪ Do not dry baby prior to use ▪ Use appropriate size, food or medical grade and heat resistant

1.6 Thermoregulation

Table 6. Thermoregulation

Aspect	Good practice point
Context	<ul style="list-style-type: none"> • Avoid hypothermia or hyperthermia, as both are potentially harmful and associated with increased morbidity and mortality • Hypothermia or cold stress may increase oxygen consumption impeding effective resuscitation
Environment³²	<ul style="list-style-type: none"> • Refer to Table 5. Resuscitation preparation • Provide a warm and draft free environment • Prewarm overhead radiant warmer or incubator <ul style="list-style-type: none"> ○ Use servo-control (if available) ○ Consider reducing set temperature when baby's axilla temperature is greater than or equal to 37.2 °C ○ Avoid covering baby with blankets—especially over temperature sensor
Observations	<ul style="list-style-type: none"> • Maintain temperature 36.5–37.5 °C • Refer to Table 9. Vital signs • If therapeutic hypothermia indicated refer to Queensland Clinical Guideline: Hypoxic-ischaemic encephalopathy⁷
Preterm and LBW	<ul style="list-style-type: none"> • Preterm babies and those who require prolonged resuscitation are particularly susceptible to hypothermia and may require additional measures to reduce heat loss³¹ • Leave baby from neck down in polyethylene bag or sheet (when used) until retrieval team arrival <ul style="list-style-type: none"> ○ Monitor baby's temperature ○ Monitor external heat source (e.g. incubator, overhead heater)³¹ • Dry baby's head and keep covered with a hat • After initial resuscitation transfer the baby to a prewarmed incubator (if available)

1.7 Investigations

All unwell babies require initial investigations to identify underlying causes. Complete further investigations as indicated after discussion with neonatologist (via RSQ).

Table 7. Investigations

Aspect	Considerations
Initial	<ul style="list-style-type: none"> • Blood <ul style="list-style-type: none"> ○ Blood glucose level (BGL) [refer to Table 16. Glucose monitoring and management] ○ Full blood count (FBC) with differential ○ Blood culture—arterial or venous sample ○ Blood gas (include lactate if available)—if signs of respiratory distress or baby being ventilated • Imaging—chest (and abdominal if indicated) x-ray(s) <ul style="list-style-type: none"> ○ Exclude air leaks and other pathologies ○ Confirm umbilical line, endotracheal tube (ETT), orogastric tube (OGT)/nasogastric tube (NGT) placement
As indicated	<ul style="list-style-type: none"> • Electrolytes • Total serum bilirubin [refer to Queensland Clinical Guideline: Neonatal jaundice⁸] • Cerebrospinal fluid (CSF) • Nasopharyngeal aspirate • Imaging—if bowel perforation is suspected, left lateral decubitus abdominal x-ray

1.8 Clinical support

Table 8. Clinical support

Aspect	Good practice point
Respiratory support	<ul style="list-style-type: none"> • Maintain a patent airway [refer to Section 4 Respiratory support]
Clinical care of baby	<ul style="list-style-type: none"> • Observe unclothed (except for nappy) • Establish intravascular (IV) access—consider umbilical venous catheter (UVC) <ul style="list-style-type: none"> ○ Avoid multiple attempts for peripheral intravenous catheter (PIVC) or umbilical access • Commence maintenance fluids [refer to Table 19. Intravascular access] • Nil by mouth (NBM) as advised • Insert NGT—if respiratory distress insert OGT size 6–8 Fr and leave on free drainage <ul style="list-style-type: none"> ○ Aspirate 4–6 hourly (unless otherwise indicated)
Skin preparation solutions^{31,33-36}	<ul style="list-style-type: none"> • No consensus and limited evidence for optimal skin preparation solution³⁶ • Can burn and damage sensitive newborn skin (e.g. when used for IV, UVC or intercostal catheter (ICC) procedures) • Use all solutions sparingly on the smallest skin area necessary <ul style="list-style-type: none"> ○ Apply caution with alcohol, detergent excipients or chlorhexidine in solution³¹ ○ Dab on gently and allow solution to dry ○ Avoid pooling of solution on or under baby—remove wet bed linen • Babies less than or equal to 1000 grams or less than or equal to 28+0 weeks, are at increased risk of skin burns <ul style="list-style-type: none"> ○ Use aqueous chlorhexidine 0.1% ○ If not available, use other solutions with caution, gently wash skin with 0.9% sodium chloride³⁶ or sterile water after procedure completed ○ Change wet linen as indicated and place baby in dry polyethylene bag • If baby greater than 1000 grams or 28+0 weeks, follow local protocols
Developmental care³⁷	<ul style="list-style-type: none"> • Positioning—provide flexion, containment and midline alignment • Handling—organise and coordinate care to minimise disturbance • Environmental—reduce noise and light • Encourage parental contact—touching and hand containment
Hygiene and comfort	<ul style="list-style-type: none"> • Assess pressure areas from temperature or SpO₂ sensors, or baby position—note SpO₂ sensor position • Perform 4–6 hourly—mouth care, nappy change, position change and pressure area care, repositioning of SpO₂ and temperature sensors <ul style="list-style-type: none"> ○ Record position of baby

2 Observations and monitoring

Unwell babies require continuous monitoring and observation as their condition may change rapidly. Document observations hourly unless they become abnormal then increase the frequency as indicated.

2.1 Vital signs

Table 9. Vital signs

Aspect	Good practice point
General	<ul style="list-style-type: none"> • Colour—pink, pale, acrocyanotic, cyanotic, jaundiced, mottled • Skin integrity—presence of bruising, rashes, skin breaks, lesions • Capillary refill time³⁸: <ul style="list-style-type: none"> ○ Measure on sternum or head ○ Normal: less than or equal to two seconds • Activity—alert, lethargic • Tone—normal, hypotonic, hypertonic • Movement—normal, abnormal <ul style="list-style-type: none"> ○ Refer to Queensland Clinical Guideline: Neonatal seizures¹⁵ • Abdomen—soft, distended, masses, bowel sounds, anus patent • Umbilicus—dry, ooze, clamp secure • IV site [refer to Table 19. Intravascular access] • Refer to Queensland Clinical Guideline: Newborn baby assessment (routine)
Temperature	<ul style="list-style-type: none"> • Normal temperature: 36.5–37.5 °C^{31,32} • Monitor skin temperature continuously (if available)³⁹ • Monitor temperature per axilla at least 4 hourly • Recheck per axilla temperature one hour after implementing additional management for an abnormal temperature
Heart rate	<ul style="list-style-type: none"> • Normal resting heart rate: <ul style="list-style-type: none"> ○ Preterm—120–160 beats per minute³⁹ ○ Term—110–160 beats per minute • Monitor continuously
Respirations	<ul style="list-style-type: none"> • Normal respiratory rate: 30–60 breaths per minute • Monitor continuously • Assess work of breathing—nasal flaring, subcostal/intercostal/sternal recession, grunting, tracheal tug • Refer to Table 11. Respiratory support • Refer to Queensland Clinical Guideline: Respiratory distress and CPAP¹³
SpO₂	<ul style="list-style-type: none"> • In the absence of good quality evidence, Queensland Neonatal Services Advisory Group (QNSAG) endorse the following consensus recommendation for SpO₂ targets after 10 minutes of age⁴⁰ <ul style="list-style-type: none"> ○ Term baby 92–98% ○ Preterm baby 90–95% • Monitor continuously and record pre-ductal measurement from right hand or wrist <ul style="list-style-type: none"> ○ Simultaneous pre- and post-ductal measurements as indicated or advised • Monitor oxygen requirement
Blood pressure	<ul style="list-style-type: none"> • Acceptable minimum mean arterial pressure is equivalent to or greater than the baby's gestational age (weeks)³⁹ • Monitor hourly including mean arterial pressure using cuff appropriate to baby's size⁴¹ • Significant elevation in mean arterial pressure may be pathological and indicative of a central nervous system event <ul style="list-style-type: none"> ○ Discuss with neonatologist regarding investigation and management • If suspected congenital cardiac condition refer to Section 12.3 Cardiac disorders

3 Fluids and medication

Table 10. Fluid and medication

Aspect	Good practice point
Fluid intake	<ul style="list-style-type: none"> NBM 10% glucose infusion rate [refer to Table 19. Intravascular access]
BGL	<ul style="list-style-type: none"> Maintain BGL greater than or equal to 2.6 mmol/L (if baby is less than 48 hours of age) Refer Table 16. Glucose monitoring and management Refer to Queensland Clinical Guideline: Newborn hypoglycaemia²¹
Output	<ul style="list-style-type: none"> Gastric aspirate—colour and volume Urine—amount, frequency, colour Bowel activity—colour, type, abnormalities (e.g. mucous plug, blood)
Medications	<ul style="list-style-type: none"> Consider antibiotic treatment <ul style="list-style-type: none"> Can be started if blood culture collection is unsuccessful Refer to Queensland Clinical Guideline: Early onset Group B Streptococcal disease⁵ Refer to Table 18. Management of sepsis Document time administered and response for any medication administered Refer to Queensland Clinical Guidelines: NeoMedQ

4 Respiratory support

Additional respiratory support may be required when the baby has increased work of breathing with increased oxygen requirements to maintain SpO₂. Refer to Queensland Clinical Guidelines: [Respiratory distress and CPAP](#)¹³ and [Neonatal resuscitation](#)¹⁴.

Table 11. Respiratory support

Aspect	Good practice point
Airway	<ul style="list-style-type: none"> Position supine with head in neutral or slightly extended position (sniffing position)⁴² If suctioning is required—use a large bore catheter <ul style="list-style-type: none"> Term baby—size 8, 10 or 12 Fr Preterm baby—size 8 or 10 Fr Do not exceed 100 mmHg negative pressure⁴² If required, insert an oropharyngeal airway If continuous positive airway pressure (CPAP) required: <ul style="list-style-type: none"> Refer to Table 12. Continuous positive airway pressure Refer to Queensland Clinical Guideline: Respiratory distress and CPAP¹³ Endotracheal intubation: <ul style="list-style-type: none"> Refer to Table 14. Indications for IPPV Supraglottic airway device (SGAD), (e.g. laryngeal mask airway™) may be required if intubation is not possible Refer to Queensland Clinical Guideline: Neonatal resuscitation¹⁴
Mask ventilation	<ul style="list-style-type: none"> Use to provide respiratory support—CPAP or intermittent positive pressure ventilation (IPPV) at initial resuscitation or for short term use Deliver using any of: <ul style="list-style-type: none"> T-piece device—IPPV and CPAP Self-inflating bag—IPPV only Flow-inflating bag with manometer attached—IPPV and CPAP Use an appropriate size mask [refer to Queensland Clinical Guideline: Respiratory distress and CPAP¹³]
Oxygen administration	<ul style="list-style-type: none"> If available, use an air/oxygen blender and humidify Titrate oxygen concentration to maintain SpO₂ within normal range [refer to Table 9. Vital signs] Document: <ul style="list-style-type: none"> Mode of oxygen delivery (e.g. cot, nasal cannulas (high or low flow), mask, CPAP, ventilator) Concentration and flow rate being delivered

4.1 Continuous positive airway pressure

Preterm babies are prone to atelectasis due to a lack of surfactant. Disparity between chest wall and lung compliance is heightened in babies with surfactant deficiency. CPAP works by maintaining expansion of the alveoli by providing a constant positive pressure to the lungs. This prevents atelectasis and allows gas exchange.⁴³

Continuous positive airway pressure (CPAP) provides a continuous distending airway pressure that facilitates the maintenance of increased transpulmonary pressure during the entire respiratory cycle. It assists to maintain functional residual capacity and assists with gas exchange.⁴⁴

Table 12. Continuous positive airway pressure

Aspect	Consideration
Indications	<ul style="list-style-type: none"> • Spontaneous respirations • Correct respiratory failure (e.g. respiratory distress syndrome (RDS)) • Treat airway obstruction • Prevent respiratory failure (e.g. apnoea of prematurity) • Signs of respiratory distress: <ul style="list-style-type: none"> ○ Increased work of breathing—tachypnoea, apnoeic episode, sternal recession, nasal flaring, audible expiratory grunt ○ Oxygen requirement greater than 30% to maintain SpO₂ [Refer to Table 9. Vital signs]
Contraindications	<ul style="list-style-type: none"> • Specific congenital anomalies or surgical conditions <ul style="list-style-type: none"> ○ Refer to Queensland Clinical Guideline: Respiratory distress and CPAP¹³
CPAP	<ul style="list-style-type: none"> • CPAP may be delivered by: <ul style="list-style-type: none"> ○ Flow inflating bag and mask ○ T-piece device and mask ○ Bi-nasal prongs ○ Nasal mask ○ Single nasopharyngeal tube ○ Bubble device ○ Ventilator • For CPAP settings and other care refer to Queensland Clinical Guideline: Respiratory distress and CPAP¹³
Observations	<ul style="list-style-type: none"> • Record hourly <ul style="list-style-type: none"> ○ Type of CPAP delivery device (e.g. mask, bi-nasal prongs) ○ CPAP pressure ○ Oxygen concentration ○ Flow rate of oxygen/air mix ○ Humidifier temperature • Observe for signs of deterioration or CPAP failure [refer to Queensland Clinical Guideline: Respiratory distress and CPAP¹³]

4.2 Surfactant

Respiratory distress syndrome (also known as hyaline membrane disease) is caused by surfactant deficiency in the preterm baby. The administration of exogenous surfactant to the baby soon after birth is known to reduce surface tension of the alveoli and improve lung expansion and gas exchange.

Table 13. Surfactant

Aspect	Considerations
Indications ^{45,46}	<ul style="list-style-type: none"> Baby requiring intubation and ventilation from birth who is: <ul style="list-style-type: none"> Less than 32 weeks gestation Any gestation with respiratory distress syndrome
Medication	<ul style="list-style-type: none"> Surfactant may be: <ul style="list-style-type: none"> <i>Curosur</i>^{®*} (<i>Poractant alfa</i>)—refer to NeoMedQ: Curosur⁴⁷ <i>Survanta</i>^{®*} (<i>Beractant</i>)—refer to NeoMedQ: Survanta⁴⁸
Administration	<ul style="list-style-type: none"> Give at time of intubation (if available) May be given from birth up to 24 hours of life Continue IPPV after administration of surfactant until the retrieval team arrives⁴⁹ Observe for changes in lung compliance and adjust ventilation pressures accordingly

*Refer to current pharmacopeia

4.3 Intermittent positive pressure ventilation

Following intubation, intermittent positive pressure ventilation (IPPV) is required. Connect the baby to a neonatal ventilator. If a neonatal ventilator is not available it may be necessary to provide IPPV via a T-piece device, self-inflating bag or flow-inflating bag.

Refer to Queensland Clinical Guideline: [Neonatal resuscitation](#).¹⁴

Table 14. Indications for IPPV

Aspect	Consideration
Deterioration ^{50,51}	<ul style="list-style-type: none"> Respiratory distress not improving or worsening—increased work of breathing Oxygen requirement—increasing over several hours, rapid increase over two hours or greater than 40% to maintain target SpO₂ Apnoeic episodes Blood gas showing increasing respiratory acidosis Poor gas exchange evident by blood gas pH less than 7.25 and PaCO₂ greater than 60 mmHg Baby agitated Pneumothorax⁵² [refer to Table 27. Air leaks] Consider indications for surfactant <ul style="list-style-type: none"> Refer to Table 13. Surfactant
CPAP	<ul style="list-style-type: none"> Signs of continuing or increasing work of breathing [refer to Table 12. Continuous positive airway pressure] Increasing respiratory distress whilst receiving CPAP of 8 cm H₂O <ul style="list-style-type: none"> Oxygen requirement greater than 40% Tachypnoea Sternal recession Nasal flaring Audible expiratory grunt Apnoea not responding to treatment

4.3.1 Intubation

Table 15. Intubation

Aspect	Consideration
Sedation	<ul style="list-style-type: none"> Consider rapid sequence induction (RSI) <ul style="list-style-type: none"> Refer to NeoMedQ: Morphine sulfate⁵³, Atropine⁵⁴ and Suxamethonium⁵⁵ Alternatively, consider sedation⁵⁰ <ul style="list-style-type: none"> Refer to NeoMedQ: Morphine sulfate⁵³ and Midazolam⁵⁶
Intubation	<ul style="list-style-type: none"> Consider plan for difficult airway management⁵⁷ (e.g. SGAD) Use size and insertion length/depth according to baby's weight⁵⁸ [refer to Queensland Clinical Guidelines: Neonatal resuscitation reference chart]⁵⁹ Assess correct position—refer to Queensland Clinical Guideline: Neonatal resuscitation¹⁴ Tape securely <ul style="list-style-type: none"> Apply hydrocolloid dressing to cheeks and use adhesive tape to secure ETT Secure to middle of upper lip Check ETT position on x-ray^{58,60,61} <ul style="list-style-type: none"> Correct position of ETT tip <ul style="list-style-type: none"> Visible just below the medial ends of the clavicles Approximately at the level of the first to second thoracic vertebrae Mid trachea above the carina (1–2 cm)
Ventilator settings	<ul style="list-style-type: none"> Peak inspiratory pressure (PIP) 18–20 cm H₂O <ul style="list-style-type: none"> May need adjustment <ul style="list-style-type: none"> To achieve physiological chest wall movement After blood gas analysis Positive end expiratory pressure (PEEP) 6–8 cm H₂O Inspiratory time 0.3–0.4 seconds Ventilator rate 40–60 breaths per minute Oxygen to maintain SpO₂ [refer to Table 9. Vital signs] Ventilator flow rate of 8 L per minute (air/oxygen mix) Provide warmed humidified air/oxygen⁶² at 37 °C
ETT suction	<ul style="list-style-type: none"> Only suction if required⁵⁸ For suction catheter sizes no more than half the internal diameter of ETT⁶³—refer to Queensland Clinical Guidelines: Neonatal resuscitation reference chart⁵⁹ If flow sensor is attached, remove prior to ETT suction Use access port in ventilator circuit <ul style="list-style-type: none"> If no access port, briefly disconnect manifold to suction Insert suction catheter the length of the ETT plus the length of manifold (if in situ)

5 Glucose monitoring

Table 16. Glucose monitoring and management

Aspect	Good practice point
Hypoglycaemia prevention and management	<ul style="list-style-type: none"> Commence 10% glucose IV infusion as soon as practical after birth to avoid hypoglycaemia [refer to Table 19. Intravascular access] Usually, glucose 4–6 mg/kg/minute (60–90 mL/kg/day) is sufficient Glucose concentrations greater than 12% require administration via UVC⁶⁴
BGL monitoring	<ul style="list-style-type: none"> Maintain BGL equal to or greater than 2.6 mmol/L Refer to Queensland Clinical Guideline: Newborn hypoglycaemia⁶

6 Infection

Early onset of sepsis is generally acquired vertically from bacteria colonizing the mother's lower genital tract or from infected amniotic fluid.⁶⁵⁻⁶⁷ Consider sepsis in any baby who is unwell or has signs of respiratory distress. Group B *Streptococcus* is recognised as the most frequent cause of early onset neonatal sepsis.⁶⁵ Refer to Queensland Clinical Guideline: [Early onset Group B Streptococcal disease](#)⁵

6.1 Risk factors and signs of infection

Table 17. Risk factors and signs of sepsis

Aspect	Consideration
Risk factors ⁶⁶	<ul style="list-style-type: none"> • Maternal: <ul style="list-style-type: none"> ○ Intrapartum fever ○ Chorioamnionitis ○ Prolonged rupture of membranes ○ Group B Streptococcal colonisation or bacteriuria ○ Other infections—herpes, hepatitis B, syphilis • Neonatal: <ul style="list-style-type: none"> ○ Prematurity—less than 37+0 weeks gestation ○ Birthweight less than 2500 grams ○ Birth asphyxia ○ Meconium liquor ○ Congenital anomalies (e.g. abdominal wall or spinal)
Signs ^{67,68}	<ul style="list-style-type: none"> • Temperature instability: <ul style="list-style-type: none"> ○ Hypothermia or hyperthermia • Respiratory: <ul style="list-style-type: none"> ○ Tachypnoea, grunting, nasal flaring ○ Increasing oxygen requirement ○ Apnoea ○ Respiratory acidosis ○ Radiologic evidence—pneumonia or plural effusion • Cardiovascular: <ul style="list-style-type: none"> ○ Tachycardia, bradycardia or arrhythmias ○ Hypotension or hypertension ○ Mottled skin, delayed capillary refill—greater than two seconds, pallor • Neurological: <ul style="list-style-type: none"> ○ Abnormal movements—jitteriness ○ Lethargy ○ Irritability ○ Seizures ○ Hypotonia or hypertonia ○ Abnormal cry—high-pitched ○ Bulging fontanelle • Other: <ul style="list-style-type: none"> ○ Lethargy ○ Feed intolerance, abdominal distention ○ Rash, jaundice, pallor, petechiae, cool peripheries ○ Hepatomegaly, splenomegaly ○ BGL instability—hypoglycaemia or hyperglycaemia ○ Metabolic acidosis

6.2 Management of sepsis

Table 18. Management of sepsis

Aspect	Consideration
Investigations	<ul style="list-style-type: none"> Collect blood culture first (1 mL if possible), then FBC with differential prior to commencing antibiotics⁶⁷ Commence antibiotics as soon as possible <ul style="list-style-type: none"> If unable to collect blood culture or FBC, do not delay administration If IV/UVC access is not obtained and sepsis is clinically suspected administer antibiotics by intramuscular (IM) injection
Management	<ul style="list-style-type: none"> Where local guidelines do not exist, suggested empirical antibiotic therapy includes: <ul style="list-style-type: none"> Penicillin* OR amoxicillin/ampicillin* AND gentamicin* <ul style="list-style-type: none"> For dosing regimens refer to NeoMedQ: Benzylpenicillin⁶⁹, Amoxicillin⁷⁰, Ampicillin⁷¹, Gentamicin⁷² Consider maternal history (e.g. if <i>Herpes simplex</i> virus is suspected consider acyclovir*)⁶⁶ <ul style="list-style-type: none"> For dosing regimens refer to NeoMedQ: Aciclovir⁷³ If late onset (greater than 72 hours old) sepsis is suspected, consider Ampicillin* and gentamicin*, OR cefotaxime* <ul style="list-style-type: none"> For dosing regimens refer to NeoMedQ: Ampicillin⁷¹, Gentamicin⁷² and Cefotaxime⁷⁴

*Refer to pharmacopeia

7 Circulation

Premature and unwell babies require intravenous access for administration of fluids and medications.

7.1 Fluid management

Table 19. Intravascular access

Aspect	Considerations
Indications	<ul style="list-style-type: none"> Signs of infection [refer to Table 17. Risk factors and signs of sepsis] Birthweight less than 1800 grams Less than 34+0 weeks gestation Respiratory distress⁷⁵ Gastrointestinal anomalies or obstruction⁷⁶ Suspected congenital cardiac disease⁷⁷ IV medication or fluid administration⁷⁸ Avoid UVC if known or suspected transposition of the great arteries (TGA)
Insertion	<ul style="list-style-type: none"> Skin preparation [refer to Table 8. Clinical support] Peripheral IV cannulation—use a 24 gauge IV cannula if available <ul style="list-style-type: none"> Splint and tape securely Observe cannula site continuously for patency, redness, infiltration Umbilical venous catheterisation—consider insertion if: <ul style="list-style-type: none"> PIVC insertion is unsuccessful and/or Baby is critically unwell or LBW Use double lumen catheter (if available)—secure with suture and tape Nurse supine—observe site for redness, leakage, dislodgement Confirm position on x-ray prior to infusing fluids except when using for emergency resuscitation Routine umbilical or peripheral arterial line insertion is not required
Maintenance fluids	<ul style="list-style-type: none"> Day one requirements <ul style="list-style-type: none"> Term baby 10% glucose 60 mL/kg/day (unless advised otherwise by neonatologist)^{64,79} Preterm baby 10% glucose 80 mL/kg/day If baby is more than 24 hours of age increase by 20 mL/kg/day until a maximum 120 mL/kg/day (e.g. day 3 term baby requires 100 mL/kg/day) <ul style="list-style-type: none"> Consider baby's sodium level and weight gain/loss Include all fluids infused—maintenance fluids and support medications (e.g. bolus glucose doses, dopamine)

7.2 Hypovolaemic shock

Hypovolemic shock is based on a combination of clinical signs. The appropriate management will vary according to the underlying pathophysiology.

Table 20. Cardiovascular compromise

Aspect	Consideration
Clinical signs⁸⁰	<ul style="list-style-type: none"> • Hypotension—mean arterial blood pressure measured in mmHg is less than the baby's gestational age in weeks • Pallor • Mottled skin • Tachycardia • Prolonged capillary refill (greater than two seconds) • Weak pulse • Metabolic acidosis • Blood loss • Decreased urine output
Causes	<ul style="list-style-type: none"> • Blood loss in-utero: <ul style="list-style-type: none"> ○ Placenta anomalies (e.g. umbilical cord rupture, placental abruption, placenta praevia) ○ Twin to twin transfusion syndrome • Acute blood loss (e.g. intracranial or pulmonary haemorrhage) • Plasma or fluid losses: <ul style="list-style-type: none"> ○ Congenital anomaly (e.g. gastroschisis or myelomeningocele) ○ Pleural effusion ○ Other body water loss (e.g. vomiting, gastric suctioning, evaporative via skin) • Ineffective cardiac output • Sepsis
Management	<ul style="list-style-type: none"> • Maintain adequate oxygenation⁸⁰ • Use isotonic crystalloid solution—0.9% sodium chloride 10 mL/kg IV/UVC⁴² over 20 minutes <ul style="list-style-type: none"> ○ If no improvement in blood pressure, heart rate or capillary refill and repeat dose(s) are indicated discuss with neonatologist ○ Continue maintenance fluids (in addition to bolus fluids) • If known blood loss from baby: <ul style="list-style-type: none"> ○ Follow critical blood loss protocol [refer to National Blood Authority (Australia) Patient Blood Management Guidelines Module 6: Neonatal and Paediatrics (2016)⁸¹] ○ Use cross matched, irradiated and cytomegalovirus (CMV) negative blood (if available) ○ For emergency transfusions, administer group O Rh D negative blood • Avoid rapid administration of fluids in preterm babies as this has been associated with an increased risk of intraventricular haemorrhage⁸²
Inotrope support⁸³	<ul style="list-style-type: none"> • If hypotension persists after fluid replacement, consider inotropic support (e.g. dopamine, dobutamine) • Consult with a neonatologist prior to commencing <ul style="list-style-type: none"> ○ For dosing and administration guidance refer to NeoMedQ: Dopamine⁸⁴ and Dobutamine⁸⁵ • Infuse through a UVC (preferable), or peripheral IV—observe site (e.g. for patency, blanching) • Do not infuse through a peripheral arterial line or an umbilical arterial line • Do not infuse bolus fluids or medications through an inotrope infusion line

*Refer to current pharmacopeia

8 Encephalopathy

Table 21. Encephalopathy

Aspect	Consideration
Context	<ul style="list-style-type: none"> Characterised by disturbed neurological function in the early days of life Often presents as:^{86,87} <ul style="list-style-type: none"> Reduced level of consciousness Seizures [refer to Section 8.2 Seizures] Difficulty in initiating and maintaining respiration Depression of tone and reflexes
Neurological assessment	<ul style="list-style-type: none"> Assess baby's neurological status <ul style="list-style-type: none"> Refer to Queensland Clinical Guideline: Neonatal seizures¹⁵ If abnormal neurological assessment, contact RSQ for neonatologist advice
Hypoxic ischaemic encephalopathy (HIE)	<ul style="list-style-type: none"> Neonatal encephalopathy resulting from acute peripartum or intrapartum event⁸⁸ Therapeutic hypothermia (TH) 33–34 °C commenced within 6 hours of birth, improves babies long term outcome where there has been moderate or severe injury⁸⁹ TH requires concurrent good supportive care (e.g. assisted ventilation and cardiovascular support)
Criteria for TH	<ul style="list-style-type: none"> Commence encephalopathy assessment, including hourly SARNAT scoring for six hours from birth <ul style="list-style-type: none"> Refer to Queensland Clinical Guideline: Encephalopathy severity (modified Sarnat) assessment⁹⁰ If HIE is suspected, contact RSQ promptly for discussion with a neonatologist If criteria for therapeutic hypothermia (TH) is met this is started before six hours of age when the baby: <ul style="list-style-type: none"> Has evidence of perinatal/intrapartum hypoxia Is greater than or equal to 35+0 weeks gestation Is greater than or equal to 1800 grams birth weight If criteria is not met (e.g. signs of mild encephalopathy, birthweight is less than 1800 grams, less than 35+0 weeks gestation, greater than six hours of age) discuss management with a neonatologist Refer to Queensland Clinical Guideline: Hypoxic-ischaemic encephalopathy⁷

8.1 Seizures

Table 22. Seizures

Aspect	Consideration
Context	<ul style="list-style-type: none"> Clinically, a seizure is a sudden paroxysmal alteration in neurological function or behavioural, motor or autonomic function⁹¹ Neonatal seizures are classified as:⁹² <ul style="list-style-type: none"> Motor—automatisms, clonic, myoclonic, tonic Epileptic spasm Non-motor—autonomic, behavioural arrest Sequential
Assessment	<ul style="list-style-type: none"> Commence assessment of abnormal movements <ul style="list-style-type: none"> Refer to Queensland Clinical Guidelines: Flowchart Abnormal movements in newborn baby⁹³ Refer to Queensland Clinical Guidelines: Neonatal seizure and neurological observation chart⁹⁴
Management	<ul style="list-style-type: none"> Contact RSQ for neonatologist advice if baby has: <ul style="list-style-type: none"> Seizure (confirmed or suspected) Other abnormal movements (e.g. jitteriness, excessive startles, tremor, hyperekplexia, clonus, benign neonatal sleep myoclonus) Refer to Queensland Clinical Guideline: Neonatal seizures¹⁵

9 Pain management

Untreated pain may have physiological and behavioural effects on some babies. Pain management includes minimising pain and stress during procedures and treatments while supporting the baby to cope and recover. Administer analgesia, sedation and comfort measures appropriate for the intervention(s).⁹⁵

Table 23. Pain

Aspect	Consideration
Signs⁹⁵⁻⁹⁸	<ul style="list-style-type: none"> • Physiological: <ul style="list-style-type: none"> ○ Increased heart rate, blood pressure, respiratory rate, muscle tension, oxygen consumption (increased oxygen requirements or falling SpO₂) ○ Pallor or flushing ○ Dilated pupils ○ Decrease in respiration rate and depth ○ Apnoea ○ Bradycardia (or tachycardia with bradycardic episodes) • Behavioural: <ul style="list-style-type: none"> ○ Crying, whimpering or moaning ○ Grimacing, quivering chin ○ Nasal flaring ○ Facial twitching ○ Flexing or extending extremities ○ Limb withdrawal, swiping or thrashing ○ Tone changes—hypertonic or hypotonic ○ Touch aversion ○ Activity—irritable or lethargic ○ Feeding difficulties ○ Difficult to comfort, soothe or quiet
Non-pharmacological^{95, 99-102}	<ul style="list-style-type: none"> • Indications—prior to procedures (e.g. heel prick, cannula insertion, eye examination, IM injection, tape removal, NGT insertion) • Breast milk—give few drops slowly and directly onto the tongue two minutes prior to the procedure • Skin to skin contact⁹⁶ • Non-nutritive sucking <ul style="list-style-type: none"> ○ Provide a pacifier for baby to suck with parental consent • Swaddling/containment <ul style="list-style-type: none"> ○ Hold the baby's extremities flexed and close to their trunk • Reduce environmental stimuli⁹⁶ (e.g. noise, lighting) • Limit the number of procedures performed at the same time
Pharmacological	<ul style="list-style-type: none"> • Oral sucrose^{*95,103} <ul style="list-style-type: none"> ○ Effective for reducing procedural pain (e.g. heel prick, venepuncture, cannula insertion, tape removal, NGT insertion, IM injection) ○ Refer to NeoMedQ: Sucrose¹⁰⁴ • Morphine sulphate^{*95} <ul style="list-style-type: none"> ○ Prior to intubation [refer to Table 15. Intubation] ○ During mechanical ventilation (as indicated) ○ Pre and post ICC insertion ○ Other (e.g. necrotising enterocolitis (NEC), bowel perforations) ○ Refer to NeoMedQ: Morphine sulfate¹⁰⁵ • Local anaesthetic—1% lignocaine* (e.g. prior to ICC insertion)⁹⁶ <ul style="list-style-type: none"> ○ Refer to NeoMedQ: Lidocaine¹⁰⁶

*Refer to current pharmacopeia

10 Preparation for retrieval

Provide clinical care and management to maintain normal SpO₂, temperature and BGL, and reduce the risk of deterioration while waiting for the arrival of the retrieval team. Additionally, initiate any other treatment or care the baby requires as able within the facility's service capability.

Table 24. Preparation for retrieval

Aspect	Consideration
Communication	<ul style="list-style-type: none"> • If there are changes in the baby's condition which may influence ongoing management, contact RSQ again for further discussion and advice • Initiate local protocol regarding internal communication (e.g. security services, nurse manager) • If telehealth is required, contact RSQ for further support • Discuss with parents: <ul style="list-style-type: none"> ○ Planned retrieval, including receiving hospital location ○ Any changes in baby's condition ○ Importance of breast milk (if indicated, assist with expressing)
Documentation²⁶	<ul style="list-style-type: none"> • Prepare two copies of documentation—one for retrieval service and one for tertiary facility • Provide copies of: <ul style="list-style-type: none"> ○ Maternal history—pregnancy health record ○ Antenatal history ○ Perinatal data form ○ Resuscitation record ○ Observation charts (e.g. vital signs, seizures and neurological observation, assessment of encephalopathy) ○ Medication and fluid charts ○ Progress notes • Newborn bloodspot screening test (NBST) card signed by parent
Other	<ul style="list-style-type: none"> • Confirm two identification bands are securely attached to the baby • X-rays: <ul style="list-style-type: none"> ○ Transferred on medical imaging software (e.g. picture archiving and communication system (PACS)) or ○ Hard copies • Baby's Queensland Health <i>Infant Personal Health Record (red book)</i> or if applicable, New South Wales <i>My Personal Health Record (blue book)</i>

10.1 Retrieval team

The retrieval team will require assistance with ongoing stabilisation.

Table 25. Retrieval team

Aspect	Consideration
Environment	<ul style="list-style-type: none"> • Space and power points for retrieval cot • Air and oxygen outlets • Procedure trolley(s)
Clinical handover	<ul style="list-style-type: none"> • Maternal history • Neonatal history: <ul style="list-style-type: none"> ○ Resuscitation ○ Investigations ○ Management ○ Changes in clinical condition • Parental plans for travelling to receiving facility • Parental contact information
Provide assistance	<ul style="list-style-type: none"> • Procedures (e.g. use of dressing trolley) • Organisation of services (e.g. imaging, security) • Refreshments and amenities for retrieval team
Expressed breast milk (EBM)	<ul style="list-style-type: none"> • Labelled and packaged in a container with ice to keep cold <ul style="list-style-type: none"> ○ Refer to Queensland Clinical Guideline: Establishing breastfeeding¹⁰⁷

11 Parents

If retrieval or transfer is required, it is desirable but not always possible for one parent to travel with the baby. This will depend on:

- Type of transport
- Maternal medical condition (the woman may be transferred separately if medically unwell)
- Space or weight restrictions
- Baby's clinical condition

Table 26. Parent considerations

Aspect	Good practice points
Photographs	<ul style="list-style-type: none"> • Provide opportunities for the parent(s) to take photographs <ul style="list-style-type: none"> ○ If required, provide photographs for parent(s)
Communication ^{26,108}	<ul style="list-style-type: none"> • Encourage early contact between parent(s) and baby • Outline the proposed plan of care for the baby • Gain parental consent for the retrieval/transfer • Encourage and facilitate parental interaction with baby • Keep the parents informed about their baby's condition • Support ongoing communication with the receiving facility • Offer parents debrief (if appropriate) <ul style="list-style-type: none"> ○ May also occur once the family has returned to home facility • Refer to support services (e.g. social worker, Aboriginal and/or Torres Strait Islander health worker)
Information	<ul style="list-style-type: none"> • Provide parent information about baby's condition (if available)¹⁰⁹ • Refer to Queensland Clinical Guidelines consumer information • Retrieval team will provide information about the admitting hospital
Maternal transfer	<ul style="list-style-type: none"> • Neonatal retrieval team is unable to care for the woman • If the woman requires continuing inpatient care: <ul style="list-style-type: none"> ○ Refer to RSQ for a separate transfer ○ Organise a medical referral to the accepting facility ○ Confirm approval from accepting facility bed manager
Accommodation	<ul style="list-style-type: none"> • Contact receiving facility to arrange accommodation—as soon as receiving facility is known • If no accommodation available, parents may need assistance with arranging their own accommodation <ul style="list-style-type: none"> ○ Refer to social work services

12 Specific conditions

12.1 Respiratory disorders

Respiratory distress in the newborn can be caused by a variety of underlying conditions and the appropriate treatment and management will be dependent on each specific condition. Refer to Queensland Clinical Guideline: [Respiratory distress and CPAP](#)¹³

The differential diagnosis of neonatal respiratory distress includes¹¹⁰:

- Pulmonary disorders (e.g. respiratory distress syndrome (RDS), transient tachypnoea of the newborn (TTN), meconium aspiration syndrome (MAS), air leak syndromes)
- Systemic disorders (e.g. hypothermia, hypoglycaemia, congenital heart disease)
- Structural anomalies (e.g. choanal atresia, Pierre Robin sequence, congenital diaphragmatic hernia (CDH), congenital lung anomalies)
- Sepsis

12.1.1 Air leaks—presentation and management

Table 27. Air leaks

Aspect	Good practice point
Context	<ul style="list-style-type: none"> • Can occur at any gestation • May be associated with other lung pathology (e.g. RDS, MAS) • Refer to Queensland Clinical Guideline: Respiratory distress and CPAP¹³
Presentation ⁵²	<ul style="list-style-type: none"> • Consider if: <ul style="list-style-type: none"> ○ Increasing respiratory effort ○ Decreased breath sounds on affected side ○ Tachycardia ○ Bradycardia ○ Hypotension ○ Skin mottling ○ Increasing oxygen requirements
Pneumothorax ⁵²	<ul style="list-style-type: none"> • If causing significant respiratory distress and cardiopulmonary compromise, requires urgent treatment (tension pneumothorax)¹¹¹ • Needle aspiration use 23 gauge non-retractable butterfly needle or 24 gauge IV cannula (with two-way flow) • ICC insertion: <ul style="list-style-type: none"> ○ Administer analgesia [refer to Section 9 Pain management] ○ Prepare skin [refer to Table 8. Clinical support] ○ Connect to a one-way valve drain or a one-way flutter valve drain and tape securely (do not suture) ○ Position baby supine ○ Observe catheter and document for fluttering, swinging and drainage ○ Confirm position on x-ray • Consider antibiotics [refer to Section 6 • Infection] • General management [refer to Table 8. Clinical support]
Pneumo-mediastinum ⁵²	<ul style="list-style-type: none"> • Conservative management is recommended • Continue to observe for other air leaks
Pneumo-pericardium ⁵²	<ul style="list-style-type: none"> • Conservative management is usually recommended • Observe for signs of cardiac tamponade

12.1.2 Choanal atresia

Table 28. Choanal atresia

Aspect	Consideration
Overview ¹¹²	<ul style="list-style-type: none"> • Congenital narrowing of the nasal airway at the posterior choanae (nares) • Can be unilateral or bilateral
Presentation ¹¹²⁻¹¹⁴	<ul style="list-style-type: none"> • Depends on if the obstruction is unilateral or bilateral • Obvious airway obstruction • Inability to insert an NGT • Stridor • Apnoea • Paradoxical cyanosis <ul style="list-style-type: none"> ◦ Cyanotic when settled—as babies obligatory breathe through their nose ◦ Pink when crying as breathing through an open mouth • If using binasal CPAP—baby's condition not improving
Management ¹¹⁴	<ul style="list-style-type: none"> • Insert oropharyngeal airway • Position baby prone • Intubate as required [refer to Table 14. Indications for IPPV] • Establish IV access [refer to Table 19. Intravascular access] • General management [refer to Table 8. Clinical support]

12.1.3 Pierre Robin sequence

Table 29. Pierre Robin sequence

Aspect	Consideration
Overview	<ul style="list-style-type: none"> • The association of micrognathia, glossoptosis, cleft palate and airway obstruction¹¹⁵
Presentation ^{116,117}	<ul style="list-style-type: none"> • Upper airway obstruction • May occur during wakefulness, sleep or feeding • Snoring • Apnoea • Stridor
Management	<ul style="list-style-type: none"> • Position baby prone or on side¹¹⁵ • If airway is compromised, insert oropharyngeal airway or single nasopharyngeal tube¹¹⁵ • If CPAP is required, use single nasopharyngeal tube (soft ivory ETT)¹¹⁵ <ul style="list-style-type: none"> ◦ Insertion distance—measure from nasal tip to tragus of the ear ◦ Positioned behind the tongue just above the larynx • If unable to maintain airway—endotracheal intubation may be required • If intubation is unsuccessful—consider using SGAD in babies greater than 2000 grams or greater than or equal to 34+0 weeks gestation • Establish IV access [refer to Table 19. Intravascular access] • General care [refer to Table 8. Clinical support]

12.2 Gastrointestinal disorders

Some gastrointestinal disorders may be diagnosed antenatally, and others may not be obvious or suspected until after birth. These may be a life-threatening surgical emergency.

12.2.1 Bowel anomalies

Table 30. Bowel anomalies

Aspect	Consideration
Overview	<ul style="list-style-type: none"> Narrowing or occlusion (e.g. duodenal atresia, malrotation, volvulus, meconium ileus, Hirschsprung's disease⁷⁶) Absence of a normal opening (e.g. imperforate anus¹¹⁸) An inflammation of the bowel (e.g. NEC)¹¹⁸
Antenatal diagnosis from antenatal scan¹¹⁹	<ul style="list-style-type: none"> Dilated intestinal loops 'Double bubble' (duodenal atresia)⁷⁶ 'Triple bubble' (jejunal atresia)
Pathology	<ul style="list-style-type: none"> Metabolic acidosis, thrombocytopenia, leukopenia, leucocytosis, glucose instability, hyponatraemia²
Imaging^{76,119}	<ul style="list-style-type: none"> X-rays <ul style="list-style-type: none"> Abdominal spine antero-posterior view Lateral decubitus view—baby side lying with left side down if bowel perforation suspected Signs of bowel abnormality <ul style="list-style-type: none"> Dilated loops of bowel Intestinal dilatation Thickened intestinal wall Pneumatosis intestinalis Double bubble or triple bubble appearance Air in the portal venous system or pneumoperitoneum Intraperitoneal calcification Absence of air in rectum
Presentation^{76,119}	<ul style="list-style-type: none"> Vomiting <ul style="list-style-type: none"> Bilious or non-bilious Abdominal distention and tenderness Abdominal wall discolouration Stool <ul style="list-style-type: none"> Fresh or occult blood Failure to pass meconium by 24–48 hours of age Passage of a meconium plug Non-specific signs <ul style="list-style-type: none"> Apnoea Increasing oxygen requirement Bradycardia or tachycardia Poor perfusion Hypotension Lethargy Temperature instability
Management⁷⁶	<ul style="list-style-type: none"> NBM³⁹ Insert large bore (size 8 Fr) NGT on free drainage³⁹ <ul style="list-style-type: none"> Hourly aspiration—measure gastric losses Establish IV access Commence empirical antibiotics [refer to Table 17. Risk factors and signs of sepsis] <ul style="list-style-type: none"> Consider adding metronidazole IV*—refer to NeoMedQ: Metronidazole¹²⁰ Consider analgesia and sedation [refer to Section 9 Pain management] Monitor urine output General management [refer to Table 8. Clinical support]

*Refer to current pharmacopeia

12.2.2 Abdominal wall anomalies

The majority of abdominal wall anomalies present on antenatal ultrasound.¹¹⁹

Table 31. Abdominal wall anomalies

Aspect	Consideration
Overview ^{119,121}	<ul style="list-style-type: none"> • Gastroschisis: <ul style="list-style-type: none"> ○ Abdominal contents herniate through a cleft in the abdominal wall ○ Usually to the right of the umbilicus • Exomphalos: <ul style="list-style-type: none"> ○ Abdominal wall anomaly consisting of an evisceration the internal organs in a sac ○ Covered by a three-layered sac made up of peritoneum, Wharton's jelly and amnion • Bladder exstrophy <ul style="list-style-type: none"> ○ Open abdominal wall, bladder and urethra¹²²
Presentation ^{119,122}	<ul style="list-style-type: none"> • Obvious herniation or evisceration of abdominal contents
At birth	<ul style="list-style-type: none"> • Position the cord clamp well above the lesion • Leave at least 15–20 cm length of cord
Airway management	<ul style="list-style-type: none"> • If gastroschisis: <ul style="list-style-type: none"> ○ Avoid bag and mask ventilation³¹ ○ If respiratory distress present—intubate and ventilate ○ Avoid non-invasive ventilation modes—CPAP and high flow³¹
At birth	<ul style="list-style-type: none"> • Protect the protruding abdominal contents¹²¹ <ul style="list-style-type: none"> ○ NOTE: Do not cover with a dressing or saline soaked gauze ○ Bowel bag not preferred • Cover the anomaly with cling film¹²³ (food grade): <ul style="list-style-type: none"> ○ Lie the baby supine, slide a large piece of cling film under the buttocks and back ○ Using sterile latex free gloves, place the exposed bowel to the centre of the abdomen ○ Observe that the bowel remains pink, and loosely encircle the abdomen and anomaly with the cling film ○ Ensure the cling film is not too tight and the bowel edges are not exposed to the air

12.2.3 Abdominal wall anomalies continuing care

Table 32. Continuing care

Aspect	Consideration
Positioning baby ^{123,124}	<ul style="list-style-type: none"> • Position baby supine or towards right side <ul style="list-style-type: none"> ○ Ensure baby is not lying on protruding abdominal contents • Aim to prevent pressure on the mesentery <ul style="list-style-type: none"> ○ Optimal position of bowel is midline ○ If midline position compromises the bowel—lay exposed abdominal contents on the side of the abdominal opening in relation to the umbilical cord (more commonly the right side) • Avoid undue tension on the abdominal contents or twisting of the bowel on itself <ul style="list-style-type: none"> ○ Bowel may require support and/or elevation to relieve pressure (e.g. position bowel on covered IV fluid bag) • If discolouration of the bowel is noted: <ul style="list-style-type: none"> ○ Reposition the baby ○ Reposition exposed bowel
Investigations	<ul style="list-style-type: none"> • FBC • Blood culture • BGL • Chest and abdominal x-ray
Management	<ul style="list-style-type: none"> • NBM^{123,124} • Insert large bore (size 8 Fr) NGT on free drainage <ul style="list-style-type: none"> ○ Hourly aspiration—measure gastric losses^{76,119,121} • Observe perfusion to lower limbs • Maintain normal thermogenesis^{76,119}—transfer baby to warmed incubator (if available) <ul style="list-style-type: none"> ○ Avoid heat and evaporative heat loss from abdominal contents • General management [refer to Table 8. Clinical support]
Fluid and medication management	<ul style="list-style-type: none"> • Establish peripheral IV access¹²³ • Commence maintenance fluid¹²¹ at 80 mL/kg/day <ul style="list-style-type: none"> ○ May require an increase of daily requirements after discussion with neonatologist ○ Refer to Table 19. Intravascular access • Commence prophylactic antibiotics at empirical doses and regimens^{76,119,123} [refer to Table 17. Risk factors and signs of sepsis] <ul style="list-style-type: none"> ○ Follow local protocols for empirical antibiotics or ○ Refer to Table 18. Management of sepsis • Administer analgesic and sedation [refer to Section 9 Pain management] • Monitor urine output

12.2.4 Oesophageal anomalies

Table 33. Oesophageal atresia and trachea-oesophageal fistula

Aspect	Consideration
Overview ^{125,126}	<ul style="list-style-type: none"> • Tracheo-oesophageal fistula <ul style="list-style-type: none"> ○ Abnormal connection or fistula tract between the trachea and the oesophagus • Oesophageal atresia <ul style="list-style-type: none"> ○ Oesophagus terminates in a blind-ending pouch with or without fistula to the trachea • May be associated with other congenital anomalies or may occur as part of a recognised syndrome <ul style="list-style-type: none"> ○ VATER/VACTERL association ○ CHARGE association ○ Trisomy 21
Antenatal	<ul style="list-style-type: none"> • USS^{76,125} <ul style="list-style-type: none"> ○ Polyhydramnios ○ Small or absent stomach
Presentation	<ul style="list-style-type: none"> • Postnatal:^{76,125} <ul style="list-style-type: none"> ○ Excessive oral secretions ○ Cyanosis or coughing when feeding ○ Respiratory distress ○ Abdominal distension • Unable to pass NGT/OGT to anticipated depth¹²⁵ • If oesophageal atresia on x-ray—NGT/OGT may be coiled in the oesophageal pouch in the upper mediastinum at T3^{76,119}
Management	<ul style="list-style-type: none"> • Airway <ul style="list-style-type: none"> ○ Do not use CPAP • IPPV is usually only required if respiratory distress, severe pneumonia or other associated malformation requiring respiratory support¹²⁵ • Insert Replogle® tube^{76,125} (if staff experienced with use are available) <ul style="list-style-type: none"> ○ Insert nasally or orally until resistance then withdraw 0.5–1 cm <ul style="list-style-type: none"> ▪ Document insertion depth ○ Connect to continuous negative pressure of minus 25–30 mmHg ○ Instil 0.5–1 ml of 0.9% sodium chloride at least hourly or as required to clear secretions • If Replogle® tube or experienced staff not available—insert a large bore (8–10 Fr) NGT/OGT <ul style="list-style-type: none"> ○ Leave on free drainage ○ Gently aspirate at least every 15 minutes and as required <ul style="list-style-type: none"> ▪ Excessive suctioning may cause damage to oesophagus ○ Do not instil 0.9% sodium chloride (or any other fluids) • Position baby at 30–45 °—elevate head of incubator/cot^{76,125} • NBM • Establish IV access and commence maintenance fluids [refer to Table 19. Intravascular access] • Commence prophylactic antibiotics at empirical doses and regimens [refer to Table 17. Risk factors and signs of sepsis] • Pacifier not recommended as increases production of saliva • General management [refer to Table 8. Clinical support]

12.2.5 Diaphragmatic hernia

Table 34. Diaphragmatic hernia

Aspect	Consideration
Overview	<ul style="list-style-type: none"> • An anomaly in the diaphragm that allows herniation of the abdominal contents into the chest¹²⁷ • Impedes fetal lung development that leads to varying degrees of pulmonary hypoplasia and pulmonary hypertension⁷⁶
Antenatal	<ul style="list-style-type: none"> • Polyhydramnios, mediastinal shift absence of intra-abdominal stomach bubble¹²⁷
Imaging ¹²⁷	<ul style="list-style-type: none"> • Chest and abdominal x-ray: <ul style="list-style-type: none"> ○ Bowel loops evident in chest cavity ○ Paucity of gas in abdomen ○ Mediastinal shift to opposite side ○ Absent diaphragm ○ Hypoplastic lung on same side (commonly left)⁷⁶
Presentation ^{76,127}	<ul style="list-style-type: none"> • Respiratory distress—cyanosis, tachypnoea and grunting • Cyanosis • Pulmonary hypertension • Decreased air entry on the affected side with bowel sounds heard in the chest • Flat or scaphoid abdomen • Auscultation of bowel sounds in lung fields • Increased anteroposterior diameter of thorax • Respiratory acidosis
Management ⁷⁶	<ul style="list-style-type: none"> • Airway: <ul style="list-style-type: none"> ○ Intubate and ventilate baby [refer to Table 14. Indications for IPPV] ○ Bag and mask ventilation or CPAP not recommended as can cause gastrointestinal distension and lung compression ○ Commence morphine infusion [refer to NeoMedQ: Morphine sulfate⁵³] • Insert large bore (size 8 Fr) NGT on free drainage <ul style="list-style-type: none"> ○ Hourly aspiration—measure gastric losses • NBM • Establish peripheral IV access and commence maintenance fluids [refer to Table 19. Intravascular access] • Cardiovascular support to maintain normal BP [refer to Table 20. Cardiovascular compromise] • General management [refer to Table 8. Clinical support]

12.3 Cardiac disorders

Congenital cardiac disease may not be suspected until after birth when the baby presents with clinical signs. The timing of the presentation will depend on the severity of the anomaly, the effects on the fetus in-utero and alterations in cardiovascular physiology during transitional circulation such as closing of the duct.¹²⁸

The Queensland Maternal and Perinatal Quality Council (QMPQC) recommends all newborn babies are offered pulse oximetry screening for critical congenital heart disease (CCHD).¹²⁹ Refer to Queensland Clinical Guideline: [Newborn baby assessment \(routine\)](#)¹⁰

12.3.1 Duct dependent cardiac lesions

Duct dependent lesions require the ductus arteriosus to remain patent to supply pulmonary or systemic blood flow, or to allow mixing between parallel circulations until definitive care and treatment is provided.

Table 35. Duct dependent cardiac lesions

Aspect	Consideration
Overview ^{80,130-132}	<ul style="list-style-type: none"> • Systemic blood flow: <ul style="list-style-type: none"> ○ Severe left-sided obstructive anomalies where systemic blood flow is dependent on right to left blood flow through patent ductus arteriosus (PDA) ○ Hypoplastic left heart syndrome, critical aortic stenosis, coarctation of aorta and interrupted aortic arch • Pulmonary blood flow: <ul style="list-style-type: none"> ○ Pulmonary atresia with intact VSD, critical pulmonary stenosis, pulmonary stenosis, right ventricular hypertrophy, overriding aorta • Systemic and pulmonary mixing between circulations: <ul style="list-style-type: none"> ○ Transposition of the great arteries (TGA)
Specific signs ^{80,130,132-134}	<ul style="list-style-type: none"> • Presentation may be gradual or rapid as the ductus arteriosus begins to constrict • Cyanosis not improving despite supplemental oxygen <ul style="list-style-type: none"> ○ If critical aortic stenosis, critical coarctation of the aorta—upper half of body is pink and lower half is cyanosed <ul style="list-style-type: none"> ▪ SpO₂ may be normal in lower body due to the left to right shunting of blood • Acute cardiorespiratory collapse with cardiogenic shock and/or hypoxia • Signs of heart failure (e.g. tachycardia, tachypnoea, hepatomegaly) • Heart murmur • Increased precordial activity; diminished or bounding femoral pulses • Blood pressure—greater than 20 mmHg difference between upper and lower extremities may indicate an obstruction such as coarctation of aorta • Chest x-ray—cardiomegaly, dextrocardia, abnormal cardiac silhouette (e.g. boot shaped heart with tetralogy of Fallot, egg on a string with TGA), abnormal pulmonary vascular markings, abnormal aortic arch
Non-specific signs ^{80,130}	<ul style="list-style-type: none"> • Hypotension—cardiogenic shock as the PDA closes; lack of improvement or clinical deterioration despite volume resuscitation • Cardiomegaly on chest x-ray • Differential pulses • Poor peripheral perfusion—elevated lactate • Signs of respiratory distress (e.g. tachypnoea, apnoea, grunting) • Lethargy—feeding difficulties
Management	<ul style="list-style-type: none"> • Initial management—refer to Table 19. Intravascular access and Table 8. Clinical support • Record SpO₂ pre-ductally on right hand and post-ductally on either foot [refer to Queensland Clinical Guideline: Newborn baby assessment (routine)¹⁰—specific targets may be identified • Establish vascular access [refer to Table 19. Intravascular access] • Commence antibiotics [refer to Table 17. Risk factors and signs of sepsis] • After discussion with neonatologist and paediatric cardiologist: <ul style="list-style-type: none"> ○ Commence IV Alprostadil (prostaglandin E1)* infusion as advised¹³⁵ [refer to NeoMedQ: Alprostadil]

*Refer to pharmacopeia

12.3.2 Non-duct dependent cardiac lesions

Table 36. Non-duct dependent cardiac lesions

Aspect	Consideration
Overview ¹³⁰	<ul style="list-style-type: none"> • Not dependent on duct for blood to mix <ul style="list-style-type: none"> ○ Tetralogy of Fallot (some) ○ VSD ○ Atrioventricular canal anomaly ○ Truncus arteriosus • Symptoms are related to excessive pulmonary blood flow
Presentation ¹³⁶	<ul style="list-style-type: none"> • Signs may develop gradually • May present with signs of congestive heart failure <ul style="list-style-type: none"> ○ Pulmonary oedema ○ Pulmonary rales ○ Hepatomegaly ○ Heart murmur ○ Tachycardia ○ Tachypnoea ○ Poor feeding ○ Diaphoresis ○ Irritability
Management ¹³³	<ul style="list-style-type: none"> • Chest x-ray <ul style="list-style-type: none"> ○ Abnormal cardiac silhouette (e.g. boot shaped heart in tetralogy of Fallot) • Monitor blood pressure—record on all four limbs • Record SpO₂ pre-ductally on right hand and post-ductally on either foot <ul style="list-style-type: none"> ○ Refer to Queensland Clinical Guideline: Newborn baby assessment (routine)¹⁰ • Commence maintenance fluids [refer to Table 16. Glucose monitoring and management] • Commence antibiotics [refer to Table 17. Risk factors and signs of sepsis] • General care [refer to Table 8. Clinical support]

12.3.3 Cardiac arrhythmias

Table 37. Cardiac arrhythmias

Aspect	Consideration
Overview	<ul style="list-style-type: none"> • Supraventricular tachycardia is the most common requiring treatment¹³⁷ • May have congenital cardiac anomaly or heart may be structurally normal
Presentation	<ul style="list-style-type: none"> • Tachycardia • Electrocardiogram (ECG) shows a narrow complex tachycardia greater than 220 beats per minute¹³⁶
Management	<ul style="list-style-type: none"> • Discuss all management with neonatal retrieval coordinator and paediatric cardiologist via RSQ • Record ECG during any treatment • Apply ice over the forehead: <ul style="list-style-type: none"> ○ Cover cool/gel packs with sheet prior to application • Do not use carotid massage or orbital pressure • Do not immerse baby's head/face in iced water • Send copy of the baby's 12 lead ECG to paediatric cardiologist • Adenosine*—discuss with neonatologist or paediatric cardiologist prior to administration for dosing regimen and other considerations <ul style="list-style-type: none"> ○ Refer to NeoMedQ: Adenosine¹³⁸

*Refer to current pharmacopeia

12.4 Neural tube anomalies

The majority of neural tube anomalies are diagnosed antenatally and provide opportunity for the woman to be transferred to a tertiary facility for the baby's birth.

Table 38. Neural tube anomalies

Aspect	Consideration
Overview	<ul style="list-style-type: none"> • Occur when there is incomplete closing of the vertebrae and the membranes around the spinal cord¹³⁹ • Spina bifida occulta: mildest form with skin covering the opening in the spinal column¹⁴⁰ • Meningocele: a midline anomaly in which the meninges herniate through the posterior vertebral arch¹⁴⁰ • Myelomeningocele: a midline anomaly in which the meninges, fragments of bone, cartilage and spinal cord herniate through the vertebral arches and the skin¹⁴⁰
Presentation	<ul style="list-style-type: none"> • Obvious or subtle dermal lesion in the lumbosacral region such as cutaneous dimples, cutaneous anomalies or masses or abnormal collections of hair¹⁴⁰ • Herniation may or may not have a skin covering¹⁴⁰
Specific management	<ul style="list-style-type: none"> • Protect the lesion: <ul style="list-style-type: none"> ○ Cover with food grade polyethylene (plastic) wrap encircling the body ○ Do not use adherent dressings ○ Do not use saline soaked dressing or gauze on exposed lesion • Position baby side lying or prone to minimise injury to the lesion • Do not use feet for heel pricks/capillary blood sampling (e.g. BGL) • Use non-latex gloves¹⁴⁰ when handling baby • Establish IV access [refer to Table 19. Intravascular access] <ul style="list-style-type: none"> ○ Avoid scalp veins for IV access • Commence maintenance fluids [refer to Table 16. Glucose monitoring and management] • NBM • Commence prophylactic antibiotics at empirical doses and regimens [refer to Table 17. Risk factors and signs of sepsis] • General care [refer to Table 8. Clinical support]

12.5 Other

Newborn babies may present with a variety of conditions and the appropriate treatment and management will be dependent on each specific condition. Contact RSQ for advice from a neonatologist.

12.5.1 Bone fractures

Table 39. Bone fractures

Aspect	Consideration
Overview	<ul style="list-style-type: none"> • Rare occurrence caused by: <ul style="list-style-type: none"> ○ Birth trauma ○ Metabolic bone disease • Clavicle fracture most often caused from birth trauma (e.g. shoulder dystocia)¹⁴¹ • Osteogenesis imperfecta (OI): <ul style="list-style-type: none"> ○ Inherited bone fragility conditions^{142,143} ○ Very rare ○ Clinical presentation of fracture(s) during prenatal period or at birth
Presentation¹⁴⁴	<ul style="list-style-type: none"> • History of difficult birth (e.g. shoulder dystocia) • Clinical signs: <ul style="list-style-type: none"> ○ Swelling/oedema ○ Crepitus ○ Bony prominence ○ Restricted movement ○ Limb deformity ○ Pain/discomfort • Clavicle fracture can result in restricted Moro reflex • X-ray to confirm diagnosis
Specific management	<ul style="list-style-type: none"> • Administer pain relief [refer to Table 23. Pain] • Clavicle fracture <ul style="list-style-type: none"> ○ Avoid elevation of the affected arm¹⁴⁴ • Limb fracture (e.g. femur, humerus) <ul style="list-style-type: none"> ○ Seek urgent advice from neonatologist regarding management (e.g. splinting) • If concerns of metabolic bone disease minimal handling • If managed locally, consider orthopaedic review

12.5.2 Skin conditions

Table 40. Skin conditions

Aspect	Consideration
Context ¹⁴⁵	<ul style="list-style-type: none"> • Neonatal skin integrity conditions can be a medical emergency <ul style="list-style-type: none"> ○ Early assessment and diagnosis aids management and prevention of complications
General management	<ul style="list-style-type: none"> • If available, organise clinical photography to aid diagnosis • Do not apply tapes or adhesive products to the skin • Attach identification bands to cot • Consider potential complications (e.g. hypothermia, hypernatraemia and sepsis) • Use silk sheets (if available) <ul style="list-style-type: none"> ○ Avoid bedding with loose fibres (e.g. bunny rugs) • Avoid skin breaching interventions • Insert umbilical catheter for fluids and medication administration <ul style="list-style-type: none"> ○ Suture catheter (do not secure with tape)
Epidermolysis bullosa (EB)	<ul style="list-style-type: none"> • Rare inherited group of blistering disorders <ul style="list-style-type: none"> ○ Ask about family history • Presentation:¹⁴⁶ <ul style="list-style-type: none"> ○ Extreme skin fragility and blister formation • Management:¹⁴⁵ <ul style="list-style-type: none"> ○ Avoid friction and shearing forces <ul style="list-style-type: none"> ▪ Avoid drying and unnecessary handling of the baby ○ Administer pain relief [refer to Table 23. Pain] ○ If open wounds/broken skin or blisters apply suitable foam dressing (e.g. Mepilex™ or Polymem™) <ul style="list-style-type: none"> ▪ If suitable dressings not available, cover open wounds/broken skin or blisters with cling film ○ Nurse in standard cot/bassinette—avoid overhead radiant heater ○ Ensure cord clamp is not in direct contact with skin ○ Avoid NGT ○ If blood pressure is required, do not place cuff directly on skin <ul style="list-style-type: none"> ▪ Line with soft non-adhesive non-shearing padding (e.g. Webril™) ○ If SpO₂ monitoring is required, apply low-adherent skin protection under the sensor (e.g. Mepitel one™) <ul style="list-style-type: none"> ▪ Secure probe with dressing suitable for fragile and sensitive skin (e.g. Mepitac™ or Siltape™) ○ Do not use adhesive skin temperature sensors ○ Monitor temperature using axillary thermometer
Collodion	<ul style="list-style-type: none"> • Presentation:¹⁴⁵ <ul style="list-style-type: none"> ○ Generalised taut thick tethered skin ○ Unyielding skin at birth which does not shed • Management:^{145,147} <ul style="list-style-type: none"> ○ Check blood gas and provide respiratory support as indicated ○ Liberally apply emollient to skin <ul style="list-style-type: none"> ▪ If available, use 50% liquid paraffin/50% soft paraffin (e.g. Dermeze™) ▪ Alternatively, use soft white paraffin ○ Nurse in incubator (if available) <ul style="list-style-type: none"> ▪ Provide humidification (follow manufacturer's instructions for use)
Ichthyoses	<ul style="list-style-type: none"> • Presentation:^{148,149} <ul style="list-style-type: none"> ○ Hyperkeratosis and thick, diamond-shaped scales present from birth ○ Dry skin causing skin splitting • Management:^{147,149} <ul style="list-style-type: none"> ○ Liberally apply emollient to skin <ul style="list-style-type: none"> ▪ If available, use 50% liquid paraffin/50% soft paraffin (e.g. Dermeze™) ▪ Alternatively, use soft white paraffin ○ Nurse in incubator (if available) <ul style="list-style-type: none"> ▪ Provide humidification (follow manufacturer's instructions for use)

References

1. Queensland Health. Clinical Services Capability Framework for Public and Licensed Private health facilities v3.2. [Internet]. 2014 [cited 2018 June 26]. Available from: <https://www.health.qld.gov.au>.
2. Thompson K, Gardinar J, Resnick S. Outcome of outborn infants at the borderline of viability in Western Australia: a retrospective cohort study. *Journal of Paediatrics and Child Health* 2016;52:728-33.
3. Boland R, David P, Dawson J, Doyle L. Outcomes of infants born at 22–27 weeks' gestation in Victoria according to outborn/inborn birth status. *Archives of Diseases of Child Fetal Neonatal Edition* 2017;102:153-61.
4. Queensland Clinical Guidelines. Standard care. Guideline No. MN22.50-V2-R27. [Internet]. Queensland Health. 2022. [cited 2023 January 11]. Available from: <https://www.health.qld.gov.au/qcg>.
5. Queensland Clinical Guidelines. Early onset Group B Streptococcal disease. Guideline No. MN22.20-V6-R27. [Internet]. Queensland Health. 2022. [cited 2023 January 11]. Available from: <https://www.health.qld.gov.au/qcg>.
6. Queensland Clinical Guidelines. Newborn hypoglycaemia. Guideline No. MN19.8-V12-R24. [Internet]. Queensland Health. 2019. [cited 2023 January 11]. Available from: <https://www.health.qld.gov.au/qcg>.
7. Queensland Clinical Guidelines. Hypoxic ischaemic encephalopathy (HIE). Guideline No. MN21.11-V11.R26. [Internet]. Queensland Health. 2021. [cited 2023 January 11]. Available from: <https://www.health.qld.gov.au/qcg>.
8. Queensland Clinical Guidelines. Neonatal jaundice. Guideline No. MN22.7-V9-R27. [Internet]. Queensland Health. 2022. [cited 2023 January 11]. Available from: <https://www.health.qld.gov.au/qcg>.
9. Queensland Clinical Guidelines. Neonatal medicines. Guideline No. MN19.54-V1-R24. [Internet]. Queensland Health. 2019. [cited 2023 January 11]. Available from: <https://www.health.qld.gov.au/qcg>.
10. Queensland Clinical Guidelines. Newborn baby assessment (routine). Guideline No. MN21.4-V6-R26. [Internet]. Queensland Health. 2021. [cited 2023 April 17]. Available from: <https://www.health.qld.gov.au/qcg>.
11. Queensland Clinical Guidelines. Perinatal care of the extremely preterm baby. Guideline No. MN20.32-V2-R25. [Internet]. Queensland Health. 2020. [cited 2023 May 23]. Available from: <https://www.health.qld.gov.au/qcg>.
12. Queensland Clinical Guidelines. Perinatal substance use: neonatal Guideline No. MN21.38-V3-R26. [Internet]. Queensland Health. 2021. [cited 2022 June 3]. Available from: <https://www.health.qld.gov.au/qcg>.
13. Queensland Clinical Guidelines. Respiratory distress and CPAP. Guideline No. MN20.3-V8-R25. [Internet]. Queensland Health. 2020. [cited 2023 May 23]. Available from: <https://www.health.qld.gov.au/qcg>.
14. Queensland Clinical Guidelines. Neonatal resuscitation. Guideline No. MN22.5-V6-R27. [Internet]. Queensland Health. 2022. [cited 2023 May 23]. Available from: <https://www.health.qld.gov.au/qcg>.
15. Queensland Clinical Guidelines. Neonatal seizures. Guideline No. MN22.23-V4-R27. [Internet]. Queensland Health. 2022. [cited 2023 April 17]. Available from: <https://www.health.qld.gov.au/qcg>.
16. Queensland Clinical Guidelines. Babies born too early (parent information). Guideline No. C20.32-1-V2-R25. [Internet]. Queensland Health. 2020. [cited 2023 April 17]. Available from: <https://www.health.qld.gov.au/qcg>.
17. Queensland Clinical Guidelines. Baby needing transfer (parent information). Guideline No. C18.18-1-V3-R23. [Internet]. Queensland Health. 2023. [cited 2023 November 30]. Available from: <https://www.health.qld.gov.au/qcg>.
18. Queensland Clinical Guidelines. Group B Streptococcus (GBS) in pregnancy (consumer information). Guideline No. C22.20-1-V3-R27. [Internet]. Queensland Health. 2022. [cited 2023 April 27]. Available from: <https://www.health.qld.gov.au/qcg>.
19. Queensland Clinical Guidelines. Hypoxic ischaemic encephalopathy (HIE) (parent information). Guideline No. C21.11-1-V7-R26. [Internet]. Queensland Health. 2021. [cited 2023 April 17]. Available from: <https://www.health.qld.gov.au/qcg>.
20. Queensland Clinical Guidelines. Jaundice in newborn babies (parent information). Guideline No. C22.7-1-V5-R27 [Internet]. Queensland Health. 2022. [cited 2023 April 17]. Available from: <https://www.health.qld.gov.au/qcg>.
21. Queensland Clinical Guidelines. Hypoglycaemia in a newborn baby (parent information). Guideline No. C19.8-1-V4-R24. [Internet]. Queensland Health. 2019. [cited 2023 April 17]. Available from: <https://www.health.qld.gov.au/qcg>.
22. Queensland Clinical Guidelines. Neonatal abstinence syndrome (NAS) parent information. Guideline No. C21.38-1-V2-R26. [Internet]. Queensland Health. 2021. [cited 2023 April 17]. Available from: <https://www.health.qld.gov.au/qcg>.
23. Queensland Clinical Guidelines. Newborn resuscitation (parent information). Guideline No. C22.5-1-V2-R27. [Internet]. Queensland Health. 2022. [cited 2023 April 17]. Available from: <https://www.health.qld.gov.au/qcg>.
24. Queensland Clinical Guidelines. Seizures in newborn babies (parent information). Guideline No. C22.23-1-V3-R27. [Internet]. Queensland Health. 2022. [cited 2023 April 17]. Available from: <https://www.health.qld.gov.au/qcg>.
25. Queensland Clinical Guidelines. Small baby born at term (parent information). Guideline No. C22.16-1-V2-R27. [Internet]. Queensland Health. 2022. [cited 2023 April 17]. Available from: <https://www.health.qld.gov.au/qcg>.
26. Presbury F, Robertson A. Neonatal retrieval and transport. In: Kain V, Mannix T, editors. *Neonatal Nursing Principles for Practice in Australia and New Zealand*. Chatswood Elsevier; 2018. p. 422-35.
27. Aziz K, Chadwick M, Baker M, Andrews W. Ante- and intra-partum factors that predict increased need for neonatal resuscitation. *Resuscitation* 2008;79:444-52.
28. Rojas M, Shirley K, Rush M. Perinatal transport and levels of care. In: Gardner S, Carter B, Enzman-Hines M, Hernandez J, editors. *Merenstein and Gardner's Handbook of Neonatal Intensive Care* 7th ed. St Louis: Mosby Elsevier 2011. p. 39-51.
29. Driver CP. Transfer of the surgical neonate. In: Losty PD, Flake AW, Rintala RJ, Hutson JMI, Naomi, editors. *Rickham's Neonatal Surgery*. London: Springer London; 2018. p. 185-90.
30. Queensland Clinical Guidelines. Neonatal resuscitation equipment checklist. Guideline No. F22.5-3-V3-R27. [Internet]. Queensland Health. 2022. [cited 2022 August 24]. Available from: <https://www.health.qld.gov.au/qcg>.
31. Australian and New Zealand Council on Resuscitation. ANZCOR Guideline 13.8 – The resuscitation of the newborn in special circumstances. [Internet]. 2021 [cited 2023 April 26]. Available from: <https://resus.org.au>.
32. Trevisanuto D, Testoni D, de Almeida MFB. Maintaining normothermia: why and how? *Seminars in Fetal and Neonatal Medicine* 2018;23(5):333-9.
33. August D, Marceau J, Benton J. Neonatal skin and wound care. In: Kain V, Mannix T, editors. *Neonatal Nursing Principles for Practice in Australia and New Zealand*. Chatswood: Elsevier; 2018.
34. Paternoster M, Niola M, Graziano V. Avoiding chlorhexidine burns in preterm infants. *Journal Obstetric Gynecologic & Neonatal Nursing* 2017;46(2):267-71.
35. Pettit J, DSharpe E. The effect of education on chlorhexidine use in the NICU. *Neonatal Network* 2017;36(5):294-305.
36. Sathiyamurthy S, Banerjee J, Godambe SV. Antiseptic use in the neonatal intensive care unit - a dilemma in clinical practice: an evidence based review. *World Journal of Clinical Pediatrics* 2016;5(2):159-71.
37. Soni R, Tscherning C. Family-centred and developmental care on the neonatal unit. *Paediatrics and Child Health* 2021;31(1):18-23.
38. King D, Morton R, Bevan C. How to use capillary refill time. *Archives of Diseases in Childhood: Education and Practice Edition* 2014;99:111-6.
39. Fox G, Watts T, Hoque N. Admission, discharge, and outcome. In: *Oxford Handbook of Neonatology*. Oxford: Oxford University Press; 2017. p. 51-70.

40. Queensland Neonatal Services Advisory Group. Endorsement of oxygen saturation targets. [email communication]. 2018 [cited 2023 May 5].
41. Devinc A, Keukelier H, De Savoye I, Desmet L, Smets K. Neonatal blood pressure monitoring: visual assessment is an unreliable method for selecting cuff sizes. *Acta Paediatrica* 2013;102(10):961-4.
42. Australian and New Zealand Council on Resuscitation. ANZCOR Guideline 13.4 Airway management and mask ventilation. [Internet]. 2021 [cited 2023 May 3]. Available from: <https://resus.org.au>.
43. Alexiou S, Panitch HB. Physiology of non-invasive respiratory support. *Seminars in Fetal and Neonatal Medicine* 2016;21(3):174-80.
44. Gupta S, Donn SM. Continuous positive airway pressure: to bubble or not to bubble? *Clinics in Perinatology* 2016;43(4):647-59.
45. Engle W. Surfactant-replacement therapy for respiratory distress in the preterm and term neonate. *Pediatrics* 2007;121(2):419-32.
46. Pfister RH, Soll RF. Initial respiratory support of preterm infants: the role of CPAP, the INSURE method, and noninvasive ventilation. *Clinics in Perinatology* 2012;39(3):459-81.
47. Queensland Clinical Guidelines. NeoMedQ Curosurf® (poractant alfa). Guideline No. NMedQ20.040-V1-R2. [Internet]. Queensland Health. 2020. [cited 2023 April 17]. Available from: <https://www.health.qld.gov.au/qcg>.
48. Queensland Clinical Guidelines. NeoMedQ Survanta® (beractant). Guideline No. NMedQ20.039-V1-R25. [Internet]. Queensland Health. 2020. [cited 2023 April 17]. Available from: <https://www.health.qld.gov.au/qcg>.
49. Brix N, Sellmer A, Jensen MS, Pedersen LV, Henriksen TB. Predictors for an unsuccessful INTubation-SURfactant-Extubation procedure: a cohort study. *BioMed Central Pediatrics*. [Internet]. 2014 [cited 2023 October 9]; 14:155-. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4072617/>; DOI:10.1186/1471-2431-14-155.
50. O'Connor TL. Premedication for nonemergent neonatal intubation: a systematic review. *The Journal of Perinatal & Neonatal Nursing* 2022;36(3):284-96.
51. Bamat N. Approach to mechanical ventilation in very preterm neonates. 2023. UpToDate Inc. Waltham MA. [Internet] [cited 2023 May 3]. Available from: <https://www.uptodate.com>.
52. Frernandez C. Pulmonary air leak in the newborn. 2023. UpToDate Inc. Waltham MA. [Internet] [cited 2023 May 3]. Available from: <https://www.uptodate.com>.
53. Queensland Clinical Guidelines. Morphine sulphate. Guideline No. NeoMedQ NMedQ20.032-V1-R25. [Internet]. Queensland Health. 2025. [cited 2023 April 19]. Available from: <https://www.health.qld.gov.au/qcg>.
54. Queensland Clinical Guidelines. Atropine. Guideline No. NMedQ19.007-V1-R24. [Internet]. Queensland Health. 2019. [cited 2023 August 14]. Available from: <https://www.health.qld.gov.au/qcg>.
55. Queensland Clinical Guidelines. Suxamethonium. Guideline No. NMedQ19.031-V2-R24. [Internet]. Queensland Health. 2022. [cited 2024 August 24]. Available from: <https://www.health.qld.gov.au/qcg>.
56. Queensland Clinical Guidelines. Midazolam. Guideline No. NMedQ20.033-V1-R25. [Internet]. Queensland Health. 2020. [cited 2023 Septemebr 4]. Available from: <https://www.health.qld.gov.au/qcg>.
57. Lin EE, Nelson O, Isserman RS, Henderson AA, Rintoul NE, Lioy J, et al. Management of neonatal difficult airway emergencies in the delivery room. *Pediatric Anesthesia* 2020;30(5):544-51.
58. Donn SM, Meerkov M. Laryngoscopy, tracheal intubation, and laryngeal mask airway. In: Donn SM, Mammel MC, van Kaam A, editors. *Manual of Neonatal Respiratory Care*. [Internet] 5th ed. Switzerland: Springer Nature; 2022. p. 159-72. [cited 2023 April 12]. Available from: <https://doi.org/10.1007/978-3-030-93997-7>.
59. Queensland Clinical Guidelines. Neonatal resuscitation reference chart. Guideline No. F22.5-2-V3-R27. [Internet]. Queensland Health. 2021. [cited 2023 April 17]. Available from: <https://www.health.qld.gov.au/qcg>.
60. Gray MM, Delaney H, Umoren R, Strandjord TP, Sawyer T. Accuracy of the nasal-tragus length measurement for correct endotracheal tube placement in a cohort of neonatal resuscitation simulators. *Journal of Perinatology* 2017;37(8):975-8.
61. Lacey G, Morley S, Berman L. *The chest x-ray: a survival guide*. Philadelphia: Saunders; 2008.
62. Restrepo R, Walsh B. Humidification during invasive and noninvasive mechanical ventilation: 2012. *Respiratory Care* 2012;57(5):782-8.
63. Russian CJ, Gonzales JF, Henry NR. Suction catheter size: an assessment and comparison of 3 different calculation methods. *Respiratory Care* 2014;59(1):32-8.
64. Tasker R, Acerini C, Holloway E, Lillotos P, Shah A. *Oxford handbook of paediatrics*. 3rd ed. Oxford: Oxford University Press Incorporated; 2021.
65. Royal College of Obstetricians and Gynaecologists. Prevention of early-onset neonatal Group B Streptococcal disease Guideline No. 36 3rd edition. [Internet]. 2017. [cited 2023 May 5]. Available from: <https://rcog.org.uk>.
66. American Association of Pediatrics. Management of infants at risk for group B streptococcal infections. *Pediatrics*. [Internet]. 2019 [cited 2023 April 27]; 144(2) DOI:<https://doi.org/10.1542/peds.2019-1881>.
67. Puopolo KM, Mukhopadhyay S, Frymoyer A, Benitz WE. The term newborn: early-onset sepsis. *Clinics in Perinatology* 2021;48(3):471-84.
68. Berardi A, Bedetti L, Spada C, Lucaccioni L, Frymoyer A. Serial clinical observation for management of newborns at risk of early-onset sepsis. *Current Opinions in Pediatrics* 2020;32(2):245-51.
69. Queensland Clinical Guidelines. NeoMedQ Benzylpenicillin. Guideline No. NMedQ20.13-V3-R25. [Internet]. Queensland Health. 2020. [cited 2022 June 2]. Available from: <https://www.health.qld.gov.au/qcg>.
70. Queensland Clinical Guidelines. NeoMedQ Amoxicillin. Guideline No. NMedQ20.045-V2-R25. [Internet]. Queensland Health. 2020. [cited 2022 JUne 3]. Available from: <https://www.health.qld.gov.au/qcg>.
71. Queensland Clinical Guidelines. NeoMedQ Ampicillin. Guideline No. NMedQ19.012-V5-R24. [Internet]. Queensland Health. 2019. [cited 2022 June 3]. Available from: <https://www.health.qld.gov.au/qcg>.
72. Queensland Clinical Guidelines. NeoMedQ Gentamicin. Guideline No. NMedQ20.038-V3-R25. [Internet]. Queensland Health. 2020. [cited 2022 June 3]. Available from: <https://www.health.qld.gov.au/qcg>.
73. Queensland Clinical Guidelines. NeoMedQ Acyclovir. Guideline No. NMedQ10.010-V2-R24. [Internet]. Queensland Health. 2019. [cited 2022 June 3]. Available from: <https://www.health.qld.gov.au/qcg>.
74. Queensland Clinical Guidelines. NeoMedQ Cefotaxime. Guideline No. NMedQ19.011-V2-R24. [Internet]. Queensland Health. 2019. [cited 2023 April 23]. Available from: <https://www.health.qld.gov.au/qcg>.
75. Boyle B. Management of respiratory disorders. In: Boxwell G, Petty J, Kaiser L, editors. *Neonatal Intensive Care Nursing*. 3rd ed. Abingdon, Oxon: Taylor & Francis Group; 2020.
76. Cousins Y. Neonatal surgical care. In: Boxwell G, Petty J, Kaiser L, editors. *Neonatal Intensive Care Nursing*. 3rd ed. Abingdon, Oxon: Taylor & Francis Group; 2020.
77. McCarthy N, Hoover D. Management of cardiovascular disorders. In: Boxwell G, Petty J, Kaiser L, editors. *Neonatal Intensive Care Nursing*. 3rd ed. Abingdon, Oxon: Taylor & Francis Group; 2020.
78. Hoover K. Medication practice in the neonatal unit. In: Boxwell G, Petty J, Kaiser L, editors. *Neonatal Intensive Care Nursing*. 3rd ed. Abidgon, Oxon: Tayloer& Francis Group; 2020.
79. Fox G, Watts T, Hoque N. Fluid balance: general guidelines for fluid intake. In: *Oxford handbook of neonatology*. 2nd ed. Oxford: Oxford University press; 2017. p. 74-86.

80. Fox G, Watts T, Hoque N. Cardiovascular problems. In: Oxford handbook of neonatology 2nd ed. Oxford: Oxford University Press; 2017. p. 169-234.
81. National Blood Authority (Australia). Patient blood management guidelines: module 6–neonatal and paediatrics. Canberra. [Internet]. 2016 [cited 2023 January 20]. Available from: <https://www.blood.gov.au>.
82. Huning BM, Horsch S, Roll C. Blood sampling via umbilical vein catheters decreases cerebral oxygenation and blood volume in preterm infants. *Acta Paediatrica* 2007;96(11):1617-21.
83. Morris R, Sharma A. Mechanism of action of inotropes in neonates. *Paediatrics and Child Health* 2019;29(6):249-56.
84. Queensland Clinical Guidelines. NeoMedQ Dopamine. Guideline No. NMed19.027-V1-R24. [Internet]. Queensland Health. 2019. [cited 2023 April 17]. Available from: <https://www.health.qld.gov.au/qcg>.
85. Queensland Clinical Guidelines. Dobutamine Guideline No. NMedQ19.026-V1-R24. [Internet]. Queensland Health. 2019. [cited 2023 April 17]. Available from: <https://www.health.qld.gov.au/qcg>.
86. Martinello K, Hart A, Yap S, Mitra S, Robertson N. Management and investigation of neonatal encephalopathy: 2017 update. *Archives of Diseases of Child Fetal Neonatal Edition* 2017;102:F346-F58.
87. Wu YW. Clinical features, diagnosis, and treatment of neonatal encephalopathy. 2020. UpToDate Inc. Waltham MA. [Internet] [cited 2023 March 16]. Available from: <https://www.uptodate.com>.
88. Verklan M, Walden M. Hypoxic ischaemic encephalopathy. In: Verklan M, Walden M, editors. *Core Curriculum for Neonatal Intensive Care*. 5th ed. St Louis: Elsevier; 2015. p. 761-5.
89. Jia W, Lei X, Dong W, Li Q. Benefits of starting hypothermia treatment within 6 h vs. 6-12 h in newborns with moderate neonatal hypoxic-ischemic encephalopathy. *BioMed Central Pediatrics*. [Internet]. 2018 [cited 2023 April 24]; 18(1):50- DOI:10.1186/s12887-018-1013-2.
90. Queensland Clinical Guidelines. Encephalopathy severity (modified Sarnat) assessment form. Guideline No. SW1208. [Internet]. Queensland Health. 2023. [cited 2023 April 28]. Available from: <https://www.health.qld.gov.au/qcg>.
91. Nguyen T, Wusthoff CJ. Clinical manifestations of neonatal seizures. *Pediatrics International* 2021;63(6):631-5.
92. Pressler RM, Cilio MR, Mizrahi EM, Moshé SL, Nunes ML, Plouin P, et al. The ILAE classification of seizures and the epilepsies: modification for seizures in the neonate. Position paper by the ILAE Task Force on Neonatal Seizures. *Epilepsia* 2021;62(3):615-28.
93. Queensland Clinical Guidelines. Flowchart: Abnormal movements in babies. Guideline No. F22.23-3-V2-R27. [Internet]. Queensland Health. 2022. [cited 2023 April 19]. Available from: <https://www.health.qld.gov.au/qcg>.
94. Queensland Clinical Guidelines. Seizures observation form. Guideline No. SW1209. [Internet]. Queensland Health. 2023. [cited 2023 April 28]. Available from: <https://www.health.qld.gov.au/qcg>.
95. Carter BS, Brunkhorst J. Neonatal pain management. *Seminars in Perinatology* 2017;41(2):111-6.
96. Fleishman RA, Mayock DE. Neonatal pain and stress: assessment and management. In: Gleason CA, Juul SE, editors. *Avery's Diseases of the Newborn* [Internet] 10th ed. Philadelphia: Elsevier; 2018. p. 432-45.e6. [cited 2023 March 7]. Available from: <https://www.sciencedirect.com/science/article/pii/B9780323401395000346>.
97. Salekin MS, Mouton PR, Zamzmi G, Patel R, Goldgof D, Kneusel M, et al. Future roles of artificial intelligence in early pain management of newborns. *Paediatric and Neonatal Pain* 2021;3(3):134-45.
98. Spence K. Management of pain and stress in the neonatal unit. In: Boxwell G, Petty J, Kaiser L, editors. *Neonatal Intensive Care Nursing 3rd ed*. Abingdon, Oxon: Taylor & Francis Group; 2020. p. 133-50.
99. Mangat AK, Oei J-L, Chen K, Quah-Smith I, Schmolzer GM. A review of non-pharmacological treatments for pain management in newborn infants. *Children (Basel)*. [Internet]. 2018 [cited 2023 March 7]; 5(10):130 DOI:10.3390/children5100130.
100. Bembich S, Cont G, Causin E, Paviotti G, Marzari P, Demarini S. Infant analgesia with a combination of breast milk, glucose, or maternal holding. *Pediatrics* 2018;142(3):1.
101. Inal S, Aydin Yilmaz D, Erdim L. The effectiveness of swaddling and maternal holding applied during heel blood collection on pain level of healthy term newborns randomized controlled trial. *Early Child Development and Care* 2022;192(13):2066-77.
102. Johnston C, Campbell-Yeo M, Disher T, Benoit B, Fernandes A, Streiner D, et al. Skin-to-skin care for procedural pain in neonates. *Cochrane Database of Systematic Reviews*. [Internet]. 2017, Issue 2017. Art No.: DOI:10.1002/14651858.CD008435.pub3.
103. Stevens B, J Y, Ohlsson A, S H, Shorkey A. Sucrose for analgesia in newborn infants undergoing painful procedures. *Cochrane Database of Systematic Reviews*. [Internet]. 2016, [cited 2023 March 7]. Issue Issue 7. Art No.: Art. No.: CD001069. DOI:10.1002/14651858.CD001069.pub5.
104. Queensland Clinical Guidelines. Sucrose. Guideline No. NMedQ21.066-V1-R26. [Internet]. Queensland Health. 2021. [cited 2023 April 19]. Available from: <https://www.health.qld.gov.au/qcg>.
105. Queensland Clinical Guidelines. NeoMedQ Morphine sulfate. Guideline No. NMedQ20.032-V1-R25. [Internet]. Queensland Health. 2020. [cited 2023 April 23]. Available from: <https://www.health.qld.gov.au/qcg>.
106. Queensland Clinical Guidelines. NeoMedQ Lidocaine (lignocaine). Guideline No. NMedQ22.091-V1-R27. [Internet]. Queensland Health. 2022. [cited 2023 April 19]. Available from: <https://www.health.qld.gov.au/qcg>.
107. Queensland Clinical Guidelines. Establishing breastfeeding. Guideline No. MN21.19-V4-R26. [Internet]. Queensland Health. 2016. [cited 2023 April 17]. Available from: <https://www.health.qld.gov.au/qcg>.
108. Trajkovski S, Mannix T. Family-centred care in the neonatal unit. In: Kain V, Mannix T, editors. *Neonatal Nursing Principles for Practice in Australia and New Zealand*. Chatswood: Elsevier; 2018. p. 422-35.
109. Lorié ES, Wreesmann W-J, van Veenendaal N, van Kempen A, Labrie N. Parents' needs and perceived gaps in communication with healthcare professionals in the neonatal (intensive) care unit: a qualitative interview study. *Patient Education and Counselling* 2021;104(7):1518-25.
110. Crowley M, Martin R. Respiratory problems. In: Fanaroff AA, Fanaroff JM, Klaus MH, editors. *Klaus and Fanaroff's care of the high-risk neonate*. 7th ed. St. Louis, Mo.: Elsevier; 2020. p. 190-210.
111. Okumus M, Zubarioglu AU. Neonatal pneumothorax - 10 years of experience from a single center. *The Journal Of Pediatric Research* 2020;7(2):163-7.
112. Lesciotta KM, Heuzé Y, Wang Jabs E, Bernstein JM, Richtsmeier JT. Choanal atresia and craniosynostosis: development and disease. *Plastic and Reconstructive Surgery* 2018;141(1):156-68.
113. Günel C, Başak S, Toskala E. Congenital malformations of the nose and paranasal sinuses. In: Cingi C, Bayar Muluk N, editors. *All Around the Nose: Basic Science, Diseases and Surgical Management*. Cham: Springer International Publishing; 2020. p. 171-7.
114. Isaacson G. Congenital anomalies of the nose. 2022. UpToDate Inc. Waltham MA. [Internet] [cited 2023 April 13]. Available from: <https://www.uptodate.com>.
115. Buchanan E. Syndromes with craniofacial abnormalities. 2022. UpToDate Inc. Waltham MA. [Internet] [cited 2023 April 19]. Available from: <https://www.uptodate.com>.
116. Cote A, Fanous A, Almajed A, Lacroix Y. Pierre Robin sequence: review of diagnostic and treatment challenges. *International Journal of Pediatric Otorhinolaryngology* 2015;79:451-64.

117. Rathe M, Rayyan M, Schenaers J, Dorman J, Breuls M, Verdonck A, et al. Pierre Robin sequence: Management of respiratory and feeding complications during the first year of life in a tertiary referral centre. *International Journal of Pediatric Otorhinolaryngology* 2015;79:206-12.
118. Dingeldein M. Selected gastrointestinal anomalies in the neonate. In: Martin RJ, Fanaroff AA, MC W, editors. *Fanaroff and Martin's Neonatal Perinatal Medicine: Diseases of the Fetus and Infant*. Philadelphia, PA: Elsevier; 2019. p. 1540-72.
119. Adamkin D, Radmacher P. Nutrition and selected disorders of the gastrointestinal tract. In: Fanaroff A, Fanaroff J, editors. *Klaus and Fanaroff's Care of the High-Risk Neonate*. 7th ed. St Louis, Mo: Elsevier; 2020. p. 80-128.
120. Queensland Clinical Guidelines. Metronidazole. Guideline No. NMedQ22.080-V1-R27. [Internet]. Queensland Health. 2022. [cited 2023 April 24]. Available from: <https://www.health.qld.gov.au/qcg>.
121. Schwartz MZ. Gastroschisis. In: Puri P, Höllwarth ME, editors. *Pediatric Surgery*. [Internet]. Berlin, Heidelberg: Springer; 2019. p. 161-8. [cited 2023 March 17]. Available from: <https://rdocu.be/c7NN9>.
122. Cuckow P, Bisharat M. Bladder exstrophy, epispadias, and cloacal exstrophy. In: Puri P, editor. *Pediatric Surgery*. [Internet]. Berlin, Heidelberg: Springer 2022. p. 1-20. [cited 2023 April 24]. Available from: https://doi.org/10.1007/978-3-642-38482-0_183-1.
123. Al Maawali A, Skarsgard ED. The medical and surgical management of gastroschisis. *Early Human Development* 2021;162:105459-.
124. Ferguson M. Nursing management of gastroschisis in the newborn. *Journal of Neonatal Nursing* 2017;23:40-5.
125. Höllwarth ME, Zaupa P. Oesophageal atresia. In: Puri P, Höllwarth ME, editors. *Pediatric Surgery*. 2nd ed. Berlin, Heidelberg: Springer; 2019. p. 29-40.
126. Beasley SW. Oesophageal atresia and tracheo-oesophageal fistula. *Surgery (Oxford)* 2022;40(11):708-12.
127. Puri P, Nakazawa N, Puri P, Höllwarth ME, editors. *Congenital diaphragmatic hernia*. [Internet]. Cham: Springer International Publishing; 2023 [cited 2023 March 17]. Available from: <https://rdocu.be/c7O83>.
128. Kenney P, Hoover D, Williams L, Iskersky V. Cardiovascular diseases and surgical interventions. In: Gardner S, Carter B, editors. *Merenstein and Gardner's Handbook of Neonatal Intensive Care* 7th ed. St Louis: Mosby Elsevier; 2011.
129. Queensland Health. *Queensland mothers and babies 2018-2019 Report of the Queensland Maternal and Perinatal Quality Council* 2021. [Internet]. 2022 [cited 2023 April 17]. Available from: <https://clinicalexcellence.qld.gov.au>.
130. Altman C. Identifying newborns with critical congenital heart disease. 2022. UpToDate Inc. Waltham MA. [Internet] [cited 2023 April 24]. Available from: <https://www.uptodate.com>.
131. Khanmbadkone S. Congenital heart disease. *British Medical Journal Best Practice*. [Internet]. 2019 [cited 2023 April 17]. Available from: <https://bestpractice.bmj.com>.
132. Mellander M. Diagnosis and management of life-threatening cardiac malformations in the newborn. *Seminars in Fetal & Neonatal Medicine* 2013;18:302-10.
133. Fillipps D, Bucciarelli R. Cardiac evaluation of the newborn. *Pediatric Clinics of North America* 2015;62:471-89.
134. Sadowski S. Cardiovascular disorders. In: Verklan M, Waldern M, editors. *Core Curriculum for Neonatal Intensive Care Nursing*. 5th ed. St Louis: Elsevier Saunders; 2015. p. 527-82.
135. Singh Y. Diagnosis and management of critical congenital heart defects in infants. *Paediatrics and Child Health* 2022;32(9):332-8.
136. Dolbec K, Mick N. Congenital heart disease. *Emergency Medicine Clinics of North America* 2011;29:811-27.
137. Goble M, von Alvensleben J, Panchangam C. Cardiology and the newborn. *International Journal of Child Health and Human Development* 2016;9(1):39-71.
138. Queensland Clinical Guidelines. Adenosine. Guideline No. NMedQ21.072-V1-R26. [Internet]. Queensland Health. 2021. [cited 2023 May 24]. Available from: <https://www.health.qld.gov.au/qcg>.
139. Phillips L, Burton J, Evans S. Spina bifida management. *Current Problems in Pediatric and Adolescent Health Care* 2017;47:173-7.
140. Yarimi J. Spina bifida. In: *Ferri's Clinical Advisor* 2023. [Internet]. Philadelphia: Elsevier; 2023. p. 1427.e18. [cited 2023]. Available from: <https://www-clinicalkey-com-au>.
141. Hogburg U, Fellman V, Thiblin I, Karlsson R, Wester K. Difficult birth is the main contributor to birth-related fracture and accidents to other neonatal fractures. *Acta Paediatrica* 2020;109:2040-8.
142. Borg SA, Bishop N. New diagnostic modalities and emerging treatments for neonatal bone disease. *Early Human Development*. [Internet]. 2018 [cited 2023 August 9]; 126:32-7. Available from: <https://doi.org/10.1016/j.earlhumdev.2018.08.014>.
143. Marini J, Forlino A, Bächinger H, Bishop N, Byers PH, De Paepe A, et al. Osteogenesis imperfecta. *Nature Reviews Disease Primers*. [Internet]. 2017 [cited 2023 October 3]; 17052. Available from: <https://rdocu.be/dkfuz>
DOI:<https://doi.org/10.1038/nrdp.2017.52>.
144. Laliotis N. Neonatal fractures. In: Riehl J, Szatkowski J, editors. *Current Fracture Care*. [Internet]. London: InTechOpen; 2023. [cited 2023 August 9]. Available from: 10.5772/intechopen.110167.
145. Rashid R, Goodyear H. Management of paediatric dermatological emergencies. *Paediatrics and Child Health* 2019;2(2).
146. Hill S, Murrell D. Differential diagnosis of vesiculobullous lesions. In: Hoeger P, Kinsler V, Yan A, editors. *Harper's Textbook of Pediatric Dermatology* 4th ed. Hoboken, USA: Wiley Blackwell; 2020.
147. Mazereeuw-Hautier J, Hernández-Martín A, O'Toole EA, Bygum A, Amaro C, Aldwin M, et al. Management of congenital ichthyoses: European guidelines of care, part two. *British Journal of Dermatology*. [Internet]. 2019 [cited 2023 August 9]; 180(3):484-95. Available from: <https://doi.org/10.1111/bjd.16882>.
148. Choate K. Autosomal recessive congenital ichthyoses. 2023. UpToDate Inc. Waltham MA. [Internet] [cited 2023 August 8]. Available from: <https://www.uptodate.com>.
149. Mazereeuw-Hautier J, Vahlquist A, Traupe H, Bygum A, Amaro C, Aldwin M, et al. Management of congenital ichthyoses: European guidelines of care, part one. *British Journal of Dermatology* 2019;180(2):272-81.

Appendix A Checklist: Preparation for retrieval

Contact RSQ (phone 1300 799 127) immediately if there is significant deterioration in the baby's clinical status, or if additional or unplanned interventions or treatment are required.

Prior to the retrieval team arriving check:

- Airway safety maintained
- Oxygenation optimised
- IV access secure
- Medications and fluids managed
- Thermoregulation maintained
- Patient documentation completed
- Parents communicated with and have written parent information

1. Parents:

- Consent to retrieval
- Informed of possible complications
- Advised of initial plan of care
- Have photos of baby

2. Preparation of the baby:

- Identification bands secured on baby: name (baby of [mother's name]), patient record number, date/time of birth, sex
- Document baby's first name if known
- Nil by mouth
- OGT/NGT
 - Inserted (OGT if respiratory distress/CPAP)
 - Position checked on x-ray if possible
 - Gastric contents emptied
 - Free drainage
- ETT
 - Secured at correct insertion depth
 - Position checked on x-ray (if possible)
 - Length documented
- Intravascular lines:
 - Labelled (PIVC, umbilical)
 - IV cannula securely taped
- Maintenance IV therapy (10% glucose) in progress
- Umbilical:
 - Sutured and securely taped
 - Position checked on x-ray (if possible)
- IV antibiotics administered (IM if unable to obtain IV access) after collection of blood culture (if possible)
- Continuous monitoring (cardiorespiratory and SpO₂)
- Analgesia and/or sedation administered as indicated
- Appropriate care initiated:
 - Neurodevelopment (positioning, lighting and noise reduction)
 - Skin
- Retrieval service advised of changes to baby's condition that may affect ongoing care or transport logistics

Checklist: Preparation for retrieval (continued)

3. Documentation (2 copies):

- Referral letter (including maternal obstetric history and reason for transfer)
- Neonatal medical/nursing notes
- Neonatal observation record
- Neonatal medication record:
 - Konakion
 - Antibiotics
- Hepatitis B vaccination
 - Analgesia and/or sedation
 - Other _____
- Neonatal fluid administration record
- Pathology results
- Queensland Health perinatal data collection form
- NBST card (signed by parent)
- Maternal obstetric progress notes (medical, obstetric, antenatal, intrapartum history)
- Maternal choice for baby feeding (breastfeeding/formula) documented
- Parent(s) contact details (names, address/es, phone numbers)

4. Additional requirements:

- PACS imaging made available to receiving hospital or x-ray hard copies provided
- Baby's *Infant Personal Health Record*
- Directions and contact details of the receiving hospital for parent(s)
- Social worker or Aboriginal and/or Torres Strait health worker contact
- Assistance with accommodation
- Interpreter (if required) to explain care and treatment to parents

5. Send with baby:

- Any pathology specimens (if required)
- Expressed breast milk (if available)
- Other consents (e.g. pacifier use)

Acknowledgements

Queensland Clinical Guidelines gratefully acknowledge the contribution of Queensland clinicians and other stakeholders who participated throughout the guideline development process particularly:

Working Party Clinical Leads

Ms Li-An Collie, Nurse Educator, NeoRESQ, Brisbane
Dr Lucy Cooke, Medical Director/Neonatologist, NeoRESQ, Brisbane
Dr Kirsty Devine, Neonatologist, Townsville University Hospital

QCG Program Officer

Ms Stephanie Sutherns
Ms Jacqueline Plazina

Peer Review Panel

Alecia Staines, Consumer Representative, Maternity Consumer Network
Eileen Cooke, Consumer Representative, Preterm Infants Parents Association
Erin Ransley, Paediatrician, Ipswich Hospital
Jo La Spina, Neonatal Nurse Practitioner, Mt Isa Hospital
Katelyn Effeney, Clinical Nurse Midwife, Sunshine Coast University Hospital
Katie Cullen, Nurse Educator/Registered Midwife, Kingaroy Hospital
Kerryanne Maddox, Midwifery Unit Manager, Goondiwindi Hospital
Lauren Kromoloff, Paediatrician, Torres Strait and Cape HHS
Lisa Hong, Senior Registrar, Mater Mothers' Hospital
Louise Thiele, Nurse Educator, Townsville University Hospital
Mathew Wong, Senior Registrar, Royal Brisbane and Women's Hospital
Maxine Ballinger, Clinical Nurse Consultant, Rockhampton Hospital
Melissa Melville, Nurse Unit Manager, NeoRESQ
Pita Birch, Director of Neonatology, Mater Mothers' Hospital
Seija Argyros, Neonatal Nurse Practitioner, Royal Brisbane and Women's Hospital
Shivanand Hebbandi, Paediatrician, Redlands Hospital
Yoie Thomas, Midwifery Nurse Educator, Roma Hospital

Queensland Clinical Guidelines Team

Professor Rebecca Kimble, Director
Ms Jacinta Lee, Manager
Ms Stephanie Sutherns, Clinical Nurse Consultant
Ms Cara Cox, Clinical Nurse Consultant
Ms Emily Holmes, Clinical Nurse Consultant
Ms Jacqueline Plazina, Clinical Nurse Consultant

Steering Committee

Funding

This clinical guideline was funded by Healthcare Improvement Unit, Queensland Health